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Venous thrombosis
Venous thrombosis is a condition in which an obstructive blood clot (thrombus) 
forms in a vein. Most commonly, venous thrombosis occurs in the deep veins of 
the leg. The thrombus limits blood flow through the vein, causing swelling and 
pain of the affected leg. A part of the thrombus may break off and travel through 
the bloodstream (embolize). The traveling blood clot can lodge in the lungs causing 
a pulmonary embolism. In the 19th century Rudolf Virchow postulated a theory, 
Virchow’s Triad, which proposes that venous thrombosis is caused by alterations in 
blood flow (i.e. stasis), vascular endothelial injury or alterations in the constitution 
of the blood (figure 1). The triad remains clinically relevant over 150 years later.
The average annual incidence of venous thrombosis is around 2 per 1000 indi-
viduals1;2. The incidence rises exponentially with age, from 0.001% in childhood 
to nearly 1% per year in the very old3. Among venous thrombosis patients ap-
proximately two-third manifests deep venous thrombosis of the leg and one-third 
pulmonary embolism with or without deep venous thrombosis of the leg4;5. A com-
mon consequence of deep venous thrombosis is the post-thrombotic syndrome, 
which develops in 20 to 50% of patients6. It is characterized by pain, heaviness, 
swelling and cramps in the affected leg. The disease may be fatal when complicated 
by pulmonary embolism5.
Figuren (voor titels en onderschriften van figuren zie tabellendocument) 
De grafieken zijn ook bijgevoegd als –eps bestanden. 
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Figure 1. Proposed causes of venous thrombosis by Virchow
risk Factors
Venous thrombosis is caused by both acquired and genetic risk factors7. Known 
acquired risk factors include immobilization, surgery, trauma, lupus anticoagulant, 
malignant disease, pregnancy, puerperium, and female hormones. Genetic risk 
factors are inherited abnormalities affecting blood coagulation such as deficiencies 
of the anticoagulants protein S, protein C and antithrombin. The factor V Leiden 
and the prothrombin 20210A mutation are the two most common prothrom-
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botic mutations7. Recently the contribution of lifestyle factors to the risk of venous 
thrombosis has gained interest.
An increasing number of studies indicate that obesity increases the risk of venous 
thrombosis8-15. Biological support for the relationship between obesity and the risk 
of venous thrombosis arises from studies showing an increase of prothrombotic 
factors, such as factor VII, factor VIII, factor XII and fibrinogen, with increasing 
body mass index16-18. Viewed together with the association of obesity with venous 
stasis12 a relation between obesity and an increased risk of venous thrombosis 
becomes plausible. The multicausal nature of venous thrombosis dictates that risk 
factors have to be present simultaneously to lead to disease. Because obesity and 
oral contraceptive use are common in the general population, and because factor 
V Leiden and the prothrombin 20210A mutation are the two most frequent pro-
thrombotic mutations, these are good candidates to investigate gene-environment 
interaction.
Like obesity, smoking is a well-established risk factor for arterial disease. How-
ever, the results of studies investigating the relationship between smoking and 
venous thrombosis are inconsistent9;10;12;19;20. Results vary from an adverse to a 
protective effect of smoking. A possible risk increasing effect may be mediated 
through an increase in coagulation factors in smokers compared to non smokers. 
It is well-known that smokers have higher fibrinogen levels21-25 and smoking ces-
sation causes a rapid fall in plasma fibrinogen22. Supporting data for an association 
between fibrinogen and the risk of venous thrombosis arises from ‘The Leiden 
Thrombophilia Study’ (LETS)26 and a study among African-Americans27. Given 
that smoking is still common worldwide28 it is important to address the controversy 
between study results and elucidate if there is an effect of smoking on the risk of 
venous thrombosis. In addition the joint effect of smoking and oral contraceptive 
use on venous thrombotic risk is of interest, since for arterial disease smoking has 
been shown to act synergistically with oral contraceptive use29.
Unlike obesity and smoking, moderate alcohol consumption is known for its 
protective effect on arterial cardiovascular disease30. A beneficial effect of mod-
erate alcohol consumption on the risk of venous thrombosis is also not unlikely 
considering the effect of alcohol consumption on several coagulation factors. Re-
duced levels of fibrinogen, factor VII and von Willebrand factor are reported to 
be associated with moderate alcohol consumption. In contrast heavy and binge 
alcohol drinking is associated with increased levels of fibrinogen and factor VII31. 
The effect of alcohol on venous thrombotic risk has only been investigated in a few 
studies with varying outcomes10;12;32.
In this thesis the association of obesity, smoking and alcohol consumption with 
the risk of venous thrombosis is investigated. The joint effect of overweight and 
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contraceptive use and the factor V Leiden mutation is assessed to identify possible 
high-risk groups, which could be of importance in medical practice.
There are important acquired risk factors for venous thrombosis that are limited 
to women e.g., oral contraceptive use, hormone replacement therapy, pregnancy 
and puerperium. During pregnancy, the risk of venous thrombosis is about 5-fold 
increased with an even higher risk in the postpartum period33. About 15% of ma-
ternal deaths in developed countries results from pulmonary embolism34, which 
makes pulmonary embolism the most common cause of maternal mortality in 
these countries. In women with thrombophilia the pregnancy related risk is further 
increased, with varying risk estimates from studies of different designs35. We evalu-
ated pregnancy and the postpartum period as risk factors for venous thrombosis 
and the joint effect of pregnancy with the factor V Leiden and the prothrombin 
20210A mutation.
Genetic factors also contribute to the thrombotic risk as indicated above. The two 
most common prothrombotic mutations, factor V Leiden and the prothrombin 
20210A mutation, are present in respectively five and two percent of the Caucasian 
population6;7. In addition there are various genetic variants with a lower prevalence 
and a smaller contribution to the risk of venous thrombosis than these mutations. 
A previous analysis within the LETS study found a genetic variant associated with 
reduced levels, but no deficiency, of the crucial anticoagulant protein C which 
was also associated with an increased risk of deep venous thrombosis of the leg36. 
Individuals with the homozygous CGT genotype were found to have a 50% to 100% 
greater risk of venous thrombosis than individuals who were homozygous for the 
common genotype. Two of the three polymorphisms tested in the LETS were con-
sidered as functionally different and were tested again in a French study with 394 
healthy individuals aged 20 to 60 years37. This study confirmed the link between 
the protein C gene polymorphisms and circulating protein C levels, and suggested 
a complex effect on the risk of venous thrombosis. In this thesis we investigated 
these two polymorphisms within the protein C gene and different combinations of 
these polymorphisms as risk factors for venous thrombosis.
When designing a case-control study the choice of an appropriate control 
group is very important. The various sources of control subjects in the numerous 
case-control studies performed over the years show that several options exists. 
We included two separate control groups in our study on the etiology of venous 
thrombosis and explore the consequences of the choice for a particular control 
group.
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meGa study
All research questions addressed in this thesis were studied in a large population-
based case-control study, The Multiple Environmental and Genetic Assessment of 
risk factors for venous thrombosis (MEGA study). From March 1999 till September 
2004, the MEGA study included consecutive patients with a first diagnosis of ve-
nous thrombosis. Patients were selected from the files of the anticoagulation clinics 
in Amsterdam, Amersfoort, The Hague, Leiden, Rotterdam and Utrecht. Patients 
with deep venous thrombosis of the leg, pulmonary embolism or a combination of 
these diagnoses were included in the study. Patients with deep venous thrombosis 
of the arm were also included, but are not part of the analyses presented in this 
thesis. As control subjects partners of patients were asked to participate. An ad-
ditional control group was recruited from the general population using a random 
digit dialing method.
Patients and control subjects filled in a questionnaire about putative risk factors 
for venous thrombosis. Most questions referred to a period of 12 months prior to 
the index date, i.e. the date of diagnosis of the thrombosis for patients and their 
partners and the date of filling in the questionnaire for the random control subjects. 
At least three months after withdrawal of anticoagulation the patients and their 
partners were asked to visit the anticoagulation clinic where after an overnight fast 
a blood sample was drawn. From June 2002 onwards, blood draws were no longer 
performed in patients and their partners, and sampling was restricted to DNA col-
lection by buccal swabs sent by mail. The random controls were invited for a blood 
draw within a few weeks after the questionnaire was sent. Within this group buccal 
swabs were sent when someone refused the blood draw.
outline oF this thesis
Chapter 2: We describe overweight and obesity as risk factors for venous thrombo-
sis and the joint effect of overweight and obesity together with Factor V Leiden, the 
prothrombin 20210A mutation and oral contraceptive use. In addition, body weight 
and height were also evaluated as separate risk factors for venous thrombosis.
Chapter 3: The relative risk of venous thrombosis associated with smoking is pre-
sented. We investigated smoking status, the amount of smoking, smoking duration 
and the number of pack-years as risk factors for venous thrombosis. By adjusting 
the smoking status analyses for fibrinogen levels we examined if fibrinogen levels 
were part of the mechanism behind the relationship between smoking and venous 
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1thrombosis. Also the joint effect of smoking with two major risk factors for venous 
thrombosis, oral contraceptive use and the factor V Leiden mutation, was investi-
gated.
Chapter 4: We report the association of a third lifestyle factor with the risk of 
venous thrombosis. Relative risks for different amounts of alcohol consumption 
were calculated.
Chapter 5: The risk of venous thrombosis in pregnant and post-partum women is 
presented. We studied different stages of pregnancy and the postpartum period and 
the risk in carriers of the factor V Leiden or the prothrombin 20210A mutation.
Chapter 6: We investigated the effect of two polymorphisms within the promoter 
region of the protein C gene (C/T at -2405 and A/G at -2418) on risk of venous 
thrombosis and on plasma protein C levels. In addition the combined effect of the 
two polymorphisms with factor V Leiden and oral contraceptive use was investi-
gated.
Chapter 7: By addressing different hypotheses within the MEGA study we describe 
our considerations concerning control group choice and the importance of adapta-
tion of statistical analyses to the source of controls.
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Risk of venous thrombosis: obesity and 
its joint effect with oral contraceptive 
use and prothrombotic mutations
Pomp ER, Le Cessie S, Rosendaal FR, Doggen CJM.
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summary
In the MEGA study we evaluated body weight, height and body mass index (BMI) 
as risk factors for venous thrombosis. Additionally we analyzed the joint effect of 
obesity together with oral contraceptive use and prothrombotic mutations on the 
risk of venous thrombosis. 3834 patients with a first venous thrombosis and 4683 
control subjects were included, all non-pregnant and without active malignan-
cies. Relative to those with a normal BMI (<25 kg/m2), overweight (BMI≥25 and 
BMI<30 kg/m2) increased the risk of venous thrombosis 1.7-fold (odds ratio (OR)
adj(age and sex) 1.70, 95% confidence interval (95% CI) 1.55-1.87) and obesity (BMI≥30 
kg/m2) 2.4-fold (ORadj 2.44, 95% CI 2.15-2.78). An increase in body weight and 
body height also individually increased thrombotic risk. Obese women who used 
oral contraceptives had a 24-fold higher thrombotic risk (ORadj 23.78, 95% CI 
13.35-42.34) than women with a normal BMI who did not use oral contracep-
tives. Relative to non-carriers of normal BMI, the joint effect of factor V Leiden 
and obesity led to a 7.9-fold increased risk (ORadj 7.86, 95% CI 4.70-13.15); for 
prothrombin 20210A this was a 6.6-fold increased risk (ORadj 6.58, 95% CI 2.31-
18.69). Body height, weight and obesity increase the risk of venous thrombosis, 
especially obesity in women using oral contraceptives.
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introduction
Venous thrombosis has an average annual incidence of around 2 per 1000 indi-
viduals (Oger, 2000). The incidence rises exponentially with age, from 0.001% in 
childhood to nearly 1% per year in the very old (Rosendaal, 1997). Among venous 
thrombosis patients approximately two-thirds has deep venous thrombosis of the 
leg and one-third pulmonary embolism with or without deep venous thrombosis of 
the leg (Anderson, Jr. et al, 1991; White, 2003). The disease is potentially fatal when 
complicated by pulmonary embolism (White, 2003).
Venous thrombosis is a multicausal disease caused by both acquired and genetic 
factors. Recent studies indicate that obesity increases the risk of venous thrombosis 
(Abdollahi et al, 2003; Goldhaber et al, 1997; Oren et al, 2006; Samama, 2000; Stein 
et al, 2005; Tsai et al, 2002; Vaya et al, 2002; White et al, 2000). Biological support 
for the observed relationship between obesity and coagulation, and thus the risk 
of venous thrombosis, arises from studies showing an increase of procoagulant 
factors, such as factor VII, factor VIII, factor XII and fibrinogen, with increasing 
body mass index (BMI) (Bowles et al, 2003; Rosito et al, 2004; Chan et al, 1995; De 
Pergola et al, 1997). Obesity is also associated with venous stasis (Tsai et al, 2002) 
which may increase thrombotic risk.
Although BMI is the most widely used measure of obesity no single function 
of body height and weight is likely to capture fully the ways in which height and 
weight are related to venous thrombosis (Kronmal, 1993). For this reason we will 
also evaluate body weight and height as separate risk factors for venous thrombo-
sis.
The multicausal nature of venous thrombosis dictates that risk factors are present 
simultaneously. We reported previously that oral contraceptives modified the effect 
of obesity on the risk of venous thrombosis, with a 10-fold increased risk among 
women with a BMI greater than 25 kg/m2 compared to normal weight women not 
using oral contraceptives. A 4.6-fold increased risk was found for oral contracep-
tive use among women with a BMI below 25 kg/m2 (Abdollahi et al, 2003). The 
Copenhagen City Heart Study led to reports on the joint effect of overweight and 
the factor V Leiden mutation and found a substantially increased risk in obese 
individuals with the mutation (Juul et al, 2004). Because obesity and oral contra-
ceptive use are common in the general population and factor V Leiden and the 
prothrombin mutation are the two most frequent prothrombotic mutations, these 
are good candidates to investigate gene-environment interaction. Only a very large 
study will be able to do so.
To investigate the risk of venous thrombosis due to obesity, the separate risk 
contributions of body weight and body height and the combination of obesity with 
Chapter 2
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other risk factors for venous thrombosis, we performed a large population-based 
case-control study.
methods
Study design
The Multiple Environmental and Genetic Assessment of risk factors for venous 
thrombosis (MEGA study) included consecutive patients with a first diagnosis 
of venous thrombosis. Between March 1999 and September 2004, patients were 
selected from the files of the anticoagulation clinics in Amsterdam, Amersfoort, 
The Hague, Leiden, Rotterdam and Utrecht. In the Netherlands, anticoagulation 
clinics monitor anticoagulation treatment of all patients in a geographically well-
defined area. We included patients between the age of 18 and 70 years with a first 
deep venous thrombosis of the leg, a pulmonary embolism or a combination of 
these diagnoses. Idiopathic venous thrombosis was defined as venous thrombosis 
in patients without surgery, injury, plaster cast, immobilization in the year prior to 
the thrombosis or oral contraceptive use and hormone replacement therapy at the 
time of the event.
The diagnostic methods were verified in a random sample of the overall patient 
group (n=742). Within this group the diagnosis of 97% of deep venous thrombosis 
and 78% of pulmonary embolism was objectively confirmed. The tests included 
compression ultrasonography, Doppler ultrasound, impedance plethysmography 
and contrastvenography for diagnosis of deep venous thrombosis and perfusion 
and ventilation lung scanning, spiral computer tomography and pulmonary an-
giography for pulmonary embolism.
Patients with severe psychiatric problems or those unable to speak Dutch were 
considered ineligible. Of the 6331 eligible patients 276 died soon after the venous 
thrombosis. Of the remaining 6055 patients 5051 participated (83%). Of the 
non-participants 82 persons were in the end stage of disease and 922 refused to 
participate or could not be located. Of the participants, 4637 patients (92%) filled 
in and returned the questionnaire. Participants who did not return a questionnaire 
completed a short questionnaire by phone, which did not include questions on 
body weight and height, or only participated with a blood sample or buccal swab.
Partners of patients were asked to volunteer as control subjects. From January 
2002 until September 2004, additional control subjects were recruited by using the 
random digit dialing (RDD) method (Hartge et al, 1984). Phone numbers were 
dialed at random within the geographical inclusion area of the patients. During 
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the phone call a specific person within a household (e.g. youngest woman between 
20 and 50) was asked to participate. The random control subjects were frequency 
matched to the patients with respect to age and sex. RDD is an efficient method to 
collect a nearly random sample of all individuals in the population. Only control 
subjects with no recent history of venous thrombosis were included and the same 
exclusion criteria were applied as for the patients.
Of the 5051 participating patients, 3657 had an eligible partner. One partner 
died soon after the request for participation. Of the remaining 3656 partners 2982 
participated (82%). Of the non-participants 18 were in end-stage disease, 649 
refused to participate or could not be located and for 7 persons the reason for non- 
participation was unknown. A questionnaire was returned by 2821 participating 
partners (95%).
Of the 4350 eligible RDD control subject, four died before they were able to 
participate. Of the remaining 4346 persons 3000 participated (69%). Of the non-
participants 15 were in the end stage of disease and 1331 refused to participate or 
could not be located. A questionnaire was returned by 2789 participants (93%). 
All participants gave written informed consent. The study was approved by the 
Medical Ethics Committee of the Leiden University Medical Center, Leiden, The 
Netherlands.
Data collection
Within a few weeks after diagnosis and registration at the anticoagulation clinics 
eligible patients received a letter with information about the MEGA study. Subse-
quently they were contacted by phone. If the patient was willing to participate a 
questionnaire was sent. The control subjects received the questionnaires immedi-
ately after inclusion by phone. The questionnaires included items on surgery, injury, 
plaster cast, immobilization, malignancies, pregnancy, use of oral contraceptives, 
hormone replacement therapy, body weight and body height. Most questions re-
ferred to a period of 12 months prior to the index date. For the patients and their 
partners, the index date was defined as the date of diagnosis of the thrombosis of 
the patient. The date of filling in the questionnaire was defined as the index date for 
the random control subjects.
Body mass index (BMI) was calculated by dividing body weight (kg) by squared 
height (m2). BMI was categorized according to the criteria of the World Health Or-
ganization (1998), defining a BMI between 18.5 and 25 kg/m2 in adults as normal, 
a BMI of 25 to 30 kg/m2 as overweight and a BMI equal to or greater than 30 kg/m2 
as obesity (World Health Organisation, 2000).
Chapter 2
22
Participants with missing data on body weight or body height were excluded from 
all analyses. In addition, individuals with malignancies diagnosed within 10 years 
prior to the index date and pregnant women or women that had been pregnant in 
the year before the index date were also excluded. In the analyses only partner con-
trols with a participating patient were included leading to a total of 3834 patients, 
2152 partner and 2531 random control subjects for the present analyses.
DNA collection
Within the patient group used for the analyses 3607 provided a blood sample or 
buccal swab (94%). In the combined control group 3830 blood samples or buc-
cal swabs were obtained (82%). The factor V Leiden mutation was successfully 
determined in 3600 patients and 3809 control subjects, the prothrombin 20210A 
mutation in 3601 patient and 3810 control subjects. A detailed description of blood 
collection and DNA analysis for the factor V Leiden (G1691A) and the prothrom-
bin mutation (G20210A) in the MEGA study has been published previously (Blom 
et al, 2005).
Statistical analysis
As estimates of relative risks we calculated odds ratios (ORs) and 95% confidence 
intervals (95% CI) according to the method of Woolf (Woolf, 1955). With a multiple 
logistic regression model we adjusted for age (continuous) and sex (categorical). 
Adjustment for age as a categorical variable resulted in the same risk estimates. In 
the analysis of body weight we also adjusted for body height (categorical). In the 
analyses with partners as control group, we performed a matched logistic analysis to 
adjust for similar lifestyle factors between patients and their partners (Cannegieter 
et al, 2006). In these matched analyses only patient-partner pairs were included 
(2152 pairs). In the analyses with the random control subjects an unmatched analy-
sis including all patients and random control subjects was performed. Because the 
results of the matched and the unmatched analyses showed consistent elevated 
relative risks in all the analyses, we calculated our risk estimates with a method 
that combines the matched and the unmatched analyses. This analysis took into 
account the presence of 2152 patients in both the matched and the unmatched 
analysis (see appendix). When analyzing the risk in men and women separately 
it was not possible to perform a matched analysis with the partner controls, as 
control individuals were nearly always of the opposite sex to the cases. Therefore, 
risk estimates were calculated with an unmatched analysis with all patients and the 
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random control subjects. Statistical significance was considered for P<0.05. SAS 9.1 
(SAS institute Inc, Cary, NC, USA) was used for all statistical analyses.
results
In the current analysis 3834 patients with a first venous thrombosis and 4683 
control subjects were included. Mean age of 3834 patients was 48.3 (5th-95th 
percentiles, 25.9-67.5) and of 4683 control subjects 46.9 (5th-95th percentiles, 25.1-
66.3) years. Fifty two percent (n=2008) of patients and 53% (n=2498) of control 
subjects were women. In the patient group 58% (n=2212) was diagnosed with deep 
venous thrombosis of the leg, 29% (n=1113) with a pulmonary embolism and 13% 
(n=509) with the combination of these diagnoses. In Table I relative risks of venous 
thrombosis with increasing body mass index are presented. The table presents 
the combined odds ratios for both control groups; the effects when each control 
group was used separately did not differ substantially (overweight, partner controls 
OR 1.45, 95% CI 1.26-1.67; overweight RDD controls OR 1.84, 95% CI 1.64-2.06; 
obesity partner controls OR 1.84, 95% CI 1.51-2.23; obesity RDD controls OR 2.88, 
95% CI 2.47-3.37). Among patients 42% was overweight and 21% obese, which was 
37% (overweight) and 13% (obese) among controls (Table I).
Overweight resulted in a 1.7-fold increased risk (ORadj 1.70, 95% CI 1.55-1.87) 
and obesity in a 2.4-fold increased risk of venous thrombosis (ORadj 2.44, 95% CI 
2.15-2.78) compared to the reference category with a BMI below 25 kg/m2 (Table 
I). Combining the overweight and obese categories, the odds ratio was 1.88 (95% 
CI 1.72-2.06).
In Figure 1 a more detailed relationship between body mass index and the risk of 
venous thrombosis is shown. Individuals with a body mass index between 22.5 and 
25.0 kg/m2 formed the reference category. In general the relation between BMI and 
thrombotic risk formed a J-shaped curve. In persons with the highest BMI (≥35 kg/
m2) the risk of venous thrombosis was 2.6 fold increased (ORadj 2.62, 95% CI 2.06-
3.33) compared to the reference group. With BMI as a continuous variable in the 
table i. Relative risk of venous thrombosis by categories of body mass index
BMI (kg/m2) Patients
N=3834
Partners
N=2152
RDD
N=2531
OR* 95% CI
All VT
 <25 1393 948 1409 1
 ≥25&<30 1629 880  848 1.70 1.55-1.87
 ≥30  812 324  274 2.44 2.15-2.78
VT, venous thrombosis; RDD, random digit dialing control subjects; OR, odds ratio; CI, confidence interval
*Combined OR, adjusted for age and sex
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Figure 1. Relative risk of venous thrombosis by categories of body mass index (BMI) (kg/m2).
I, 95% confidence interval; np, number of patients; nc, number of control subjects; ref., reference category.
*Adjusted for age and sex
table ii. Relative risk of venous thrombosis by categories of body mass index in different subgroups
BMI (kg/m2) Patients Control subjects OR* 95% CI
DVT
 <25 772 2357 1
 ≥25&<30 949 1728 1.83 1.63-2.06
 ≥30 491  598 2.80 2.41-3.26
PE
 <25 463 2357 1
 ≥25&<30 458 1728 1.51 1.31-1.75
 ≥30 192  598 1.89 1.55-2.31
DVT+PE
 <25 158 2357 1
 ≥25&<30 222 1728 2.05 1.64-2.57
 ≥30 129  598 3.77 2.89-4.93
Idiopathic VT
 <25 344 2357 1
 ≥25&<30 549 1728 1.84 1.55-2.17
 ≥30 221  598 2.58 2.07-3.23
All VTwomen†
 <25 823  867 1
 25-30 683  370 1.93 1.64-2.26
 ≥30 502  156 3.36 2.74-4.12
All VTmen†
 <25 569  542 1
 ≥25&<30 944  478 1.72 1.46-2.03
 ≥30 310  118 2.32 1.82-2.97
DVT, deep venous thrombosis; PE, pulmonary embolism; OR, odds ratio; CI, confidence interval 
*combined for both control groups and adjusted for age and sex; †three patients were not included in 
these analyses because two were transsexuals and one had Klinefelter syndrome, these analyses were 
performed with the random control subjects only.
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logistic model a 1.1-fold increased risk (10% increase) per 1 kg/m2 was observed 
(ORadj 1.13, 95% CI 1.11-1.16).
Odds ratios were slightly higher for deep venous thrombosis than for pulmonary 
embolism and in women than in men (Table II). The odds ratio of idiopathic ve-
nous thrombosis with increasing BMI was approximately the same as the overall 
risk (Table II).
Table III shows the relative risk of venous thrombosis by categories of body weight 
(kg) and body height (m). As was to be expected, adjusted for body height, body 
weight again was associated with thrombotic risk, which was also evident without 
adjustment for body height, but less clearly. A 2.9-fold increased risk was found 
for body weights equal to or above 110 kg (ORadj 2.93, 95% CI 2.28-3.77) relative 
to those between 70 to 79 kg. Body weights between 50 and 70 kg were associated 
with the lowest risk of venous thrombosis. Body weight was also assessed as a risk 
factor in men and women separately, with similar results (data not shown). Only 
individuals with a body height above 1.80 m had a slightly increased risk of venous 
thrombosis compared to those between 1.70 to 1.74 m. Short persons (<1.70 m) 
had a low risk of venous thrombosis. When analyzing men and women separately, 
the risk only appeared to be decreased for short men (ORadj, ≤1.79 m 0.77, 95% CI 
0.64-0.94) and increased for very tall men (ORadj, ≥1.90 m 1.32, 95% CI 1.02-1.70) 
compared to men with a body height between 1.80 and 1.84 m (data not shown).
table iii. Relative risk of venous thrombosis by categories of body weight and body height
Body weight (kg) Patients Control subjects OR* 95% CI
<50  27   38 0.68 0.40-1.16
50-59 206  396 0.60 0.49-0.73
60-69 595 1076 0.69 0.60-0.78
70-79 871 1209 1
80-89 932 1038 1.43 1.26-1.62
90-99 676  586 1.88 1.63-2.17
100-109 308  212 2.45 2.01-2.99
≥110 219  128 2.93 2.28-3.77
Body height (m)
<1.60 182  247 0.69 0.56-0.86
1.60-1.64 377  531 0.73 0.61-0.86
1.65-1.69 649  857 0.83 0.72-0.95
1.70-1.74 749  878 1
1.75-1.79 662  809 1.01 0.87-1.16
1.80-1.84 571  671 1.14 0.98-1.33
1.85-1.89 373  438 1.17 0.98-1.41
≥1.90 271  252 1.56 1.27-1.92
OR, odds ratio; CI, confidence interval
*adjusted for age, sex and body height in body weight analyses, adjusted for age and sex in body height 
analyses
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Joint effect of obesity with other risk factors for venous thrombosis
The combined effect of oral contraceptive use and obesity was examined in women 
aged 18 to 39 years (Table IV). Among women who did not use oral contraceptives 
the risk increased 2.5-fold for overweight women and 3.0-fold for obese women 
compared to normal weight women not using oral contraceptives. Relative to 
non-users of normal BMI, oral contraceptive users who were overweight had an 
11.6-fold increased risk and those who were obese a 23.8-fold increased risk.
Among non-carriers of factor V Leiden, obesity led to a 2.5-fold increased risk 
(normal BMI as reference). The joint effect of factor V Leiden and obesity resulted 
in a 7.9-fold increased risk of venous thrombosis (Table V). For obese participants 
table iV. Combined effect of body mass index and oral contraceptive (OC) use on the risk of venous 
thrombosis in women aged 18 to 39
BMI (kg/m2) OC use Patients Control subjects OR* 95% CI
<25 no  51 167  1
≥25&<30 no  27  34  2.52 1.38-4.57
≥30 no  28  30  3.04 1.66-5.57
<25 yes 260 233  4.15 2.85-6.03
≥25&<30 yes 178  55 11.63 7.46-18.14
≥30 yes 132  19 23.78 13.35-42.34
OR, odds ratio; CI, confidence interval *analyses are performed with all patients and the random control 
subjects and adjusted for age
table V. Combined effect of body mass index, the factor V Leiden (FVL) and the prothrombin (FII) 20210A 
mutation on the risk of venous thrombosis
BMI (kg/m2) FVL Patients Control subjects OR* 95% CI
<25 no 1077 1631 1
≥25&<30 no 1289 1244 1.72 1.54-1.93
≥30 no  643  423 2.48 2.13-2.88
<25 yes  217   69 4.18 3.12-5.61
≥25&<30 yes  250   58 5.77 4.20-7.93
≥30 yes  124   18 7.86 4.70-13.15
FII 20210A Patients Control subjects OR* 95% CI
<25 no 1225 1803 1
≥25&<30 no 1455 1351 1.72 1.54-1.91
≥30 no  735  477 2.45 2.12-2.82
<25 yes   70   18 4.39 2.56-7.51
≥25&<30 yes   84   20 4.51 2.64-7.72
≥30 yes   32    4 6.58 2.31-18.69
OR, odds ratio; CI, confidence interval
*Adjusted for age and sex.
Note: The inclusion of matched case control pairs in the analyses was dependent on the category (BMI, 
FVL; BMI, FII 20210A) of both partners
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with the prothrombin 20210A mutation the risk of venous thrombosis increased 
6.6-fold (normal BMI, non-carriers as reference).
discussion
In this large population-based case-control study both overweight and obesity were 
associated with a two- to three-fold increased risk of venous thrombosis. Since the 
prevalence of obesity is increasing, this has a major impact (http://www.ic.nhs.uk/
webfiles/publications/opan06/OPAN%20bulletin%20finalv2.pdf,http://www.cdc.
gov/nchs/products/pubs/pubd/hestats/overweight/overwght_adult_03.htm).  In 
this study 50% of the control subjects, who represent the general population, were 
overweight or obese. This suggests that almost one-third of all events of thrombosis 
are preventable by weight loss (population attributable risk=28%), assuming that 
weight loss reduces venous thrombotic risk (Ditschuneit et al, 1995; Hankey et 
al, 1997; Kopp et al, 2003). Prevalences of overweight and obesity reported from 
the UK and the USA of 60-65 percent lead to even higher preventable fractions 
(http://www.ic.nhs.uk/webfiles/publications/opan06/OPAN%20bulletin%20
finalv2.pdf,http://www.cdc.gov/nchs/products/pubs/pubd/hestats/overweight/
overwght_adult_03.htm).
We also evaluated body weight and height as separate risk factors for venous 
thrombosis. Body weight was positively associated with thrombotic risk in both 
men and women. For body height no substantial increased risks were found in 
women, but short men appeared to have a low risk and tall men a high risk of 
venous thrombosis. Particularly this latter is remarkable, since body height is not 
associated with the relative amount of fat, as body weight and BMI both are. The 
effect of obesity was more pronounced in women than in men, with high relative 
risks for overweight and obese women who used oral contraceptives. The joint 
effect of obesity with the factor V Leiden mutation or the prothrombin mutation 
appeared both slightly higher than the sum of the separate effects.
The association between BMI and venous thrombosis is likely to be causal 
because it is consistent over studies, shows a dose-response relation and is biologi-
cally plausible. Our results are consistent with previous studies demonstrating an 
increased risk of venous thrombosis with increasing body mass index. The Nurses 
Health Study found a three-fold increased risk of pulmonary embolism in women 
with obesity (Goldhaber et al, 1997). Another prospective follow-up study reported 
a hazard ratio of 2.3 for venous thrombosis among persons with a body mass index 
(BMI) above 30 kg/m2 compared to persons with a BMI below 25 kg/m2 (Tsai et 
al, 2002). Other studies also showed an elevated risk of venous thrombosis among 
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overweight persons (Abdollahi et al, 2003; Oren et al, 2006; Samama, 2000; Stein 
et al, 2005; Vaya et al, 2002; White et al, 2000). The magnitudes of the relative risks 
are largely similar. To our knowledge the only case-control study that did not found 
an increased risk of venous thromboses with BMI was a study with a very small 
sample size (n=90) performed in pregnant women and women during post partum 
(Danilenko-Dixon et al, 2001). It is not unlikely that BMI in these women is a poor 
marker for the relative amount of body fat. 
There are several ideas about the mechanism behind the association between 
overweight and the risk of venous thrombosis. An increase in prothrombotic fac-
tors in obese persons may play a role (Bowles et al, 2003; Rosito et al, 2004; Chan 
et al, 1995; De Pergola et al, 1997), while obesity may also be associated with lack 
of exercise and venous stasis (Tsai et al, 2002). A high body mass index can be 
the result of excess body fat or abundant muscle development. ‘The study of men 
born in 1913’ evaluated waist circumference as a measure for abdominal obesity 
instead of BMI (Hansson et al, 1999). In this study, men in the highest decile of 
waist circumference (≥100 cm) had a relative risk for DVT of 3.9 compared to 
men with a waist circumference less than 100 cm. This result suggests that obesity 
caused by excess body fat is likely to be a risk factor for venous thrombosis.
We found a more pronounced excess risk for deep vein thrombosis than for pul-
monary embolism. This is in accordance with results from the National Hospital 
Discharge Survey (Stein et al, 2005). An explanation may be the complexities of 
the diagnosis of pulmonary embolism, which may have led to misclassification, 
i.e. inclusion of some patients without a true pulmonary embolism (PIOPED, 
1990). Alternatively, clots in obese individuals may be different from those in 
non-obese people and have less tendency to embolize, as has also been suggested 
as an explanation for the low risk of pulmonary embolism in individuals with 
factor V Leiden. Obesity and factor V Leiden both lead to APC resistance (Lowe 
et al, 1999), which lends further plausibility to a differential effect of deep venous 
thrombosis and pulmonary embolism. Oral contraceptive use also leads to APC-
resistance, which helps to understand the syntergistic effect of obesity and factor 
V Leiden and obesity and oral contraceptive use. This is in line with the synergy 
between factor V Leiden and oral contraceptive use (Vandenbroucke et al, 1994) 
and a previous report on obesity and the factor V Leiden mutation (Juul et al, 
2004).
A possible limitation of our study is that height and weight were self-reported. 
If there would be a difference between patients and control subjects in over- or 
underreporting body weight or height an incorrect estimate of risk would be the re-
sult. There is no reason to expect such a difference in reporting behaviour between 
the two groups. The number of individuals who failed to report their body weight 
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was similar in patients (2.2%) and control subjects (2.6%). In general, overweight 
individuals tend to underreport and underweight individuals tend to overreport 
their body weight (Gunnell et al, 2000). If this phenomenon occurred the actual 
relative risks would even be higher.
Control subjects were drawn from two different sources. Because partners have 
similar lifestyles that may result in similar body mass indices, we performed a 
matched analysis that takes these associations into account. The matched analy-
sis adjusted for all similar lifestyle factors between partners, which may include 
some unknown, unmeasured confounders resulting in lower risk estimates for 
the matched analysis compared to the unmatched analysis using the random digit 
dialing controls. Both analyses show consistent results in terms of clearly increased 
risks.
In conclusion, overweight and obesity are risk factors for venous thrombosis in 
this large population-based case-control study. Especially obesity in women using 
oral contraceptives is associated with a very high risk. The 24-fold increased risk 
should be considered when prescribing oral contraceptives for obese women.
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aPPendix: combininG the estimates oF the conditional and 
unconditional loGistic reGression
Combining two estimates of the odds ratio
In our approach the two estimates of the log-odds ratio are combined into one 
overall log-odds ratio. Since both estimates use the same subset of cases, the 
estimates are correlated. The correlation between the two estimates is estimated 
using a sandwich estimator which is the commonly used estimator in statistics 
(Kauermann & Carroll, 2001). Details about this calculation are given later on in 
this appendix. The correlation is used to combine the two estimates in the most 
efficient way and to calculate the correct standard errors.
We consider first the case when there is only one parameter to combine. Let βˆ1 
and βˆ2 be the estimated log odds ratios in the two different analyses with respective 
standard errors s1 and s2 and let ρˆ be the estimated correlation coefficient between 
the two estimates. In this case the combined estimate is a weighted mean of βˆ1 and 
βˆ2: βˆcom = wβˆ1 + (1 − w)βˆ2 with standard error
scom = se(βˆcom) = √ w2  s12   + (1 − w)2   s22   + 2w(1 − w)ρ s1  s2  .
It is straightforward to show that the optimal weight is given by w = (s2
2 − ρˆs1s2)/(s1
2 
+ s2
2 − 2ρˆs1s2).
In general, there are two multidimensional parameters θ1 = (α1, β) and θ2 = (α2, β), 
respectively. The k-dimensional β-parameter is the shared part. The parameters α1 
and α2 of dimension k1 and k2, respectively, are not shared, for example because 
of different confounding variables in the two analyses, or because the effect of a 
confounder is expected to act differently in the two models.
Suppose that βˆ1 and βˆ1 are the two correlated estimates of the shared part β with 
covariance matrices cov(βˆ1) = C1, cov(βˆ2) = C2 and cov(βˆ1, βˆ2) = C12.
Then the most efficient estimate of β (the weighted least square estimate) is given 
by βˆcom
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Estimation of the correlation between the two estimated odds ratios
In the general situation, there are two multidimensional parameters θ1 = (α1, β1) and 
θ2 = (α2, β2), respectively. Assume that both parameters are estimated by multiple 
regression models (in our situation θ1 is estimated by conditional logistic regression 
and θ2 by unconditional logistic regression.) When fitting this models by maxi-
mum likelihood we obtain the estimated parameters θˆ1 = (αˆ1, βˆ1) and θˆ2 = (αˆ2, βˆ2), 
the Fisher-information matrices I1 and I2 and the score matrices U1 and U2, where, 
generally 
2l
θ2
I =  and li(θˆ)
θj
Uij =  is the derivative of the log-likelihood contribu-
tion of individual i with respect to parameter θj.
Due to the overlap the estimated parameters θˆ1 = (αˆ1, βˆ1) and θˆ2 = (αˆ2, βˆ2) are 
dependent. Their covariance matrix can be estimated by a sandwich estimator: 
cov(θˆ1, θˆ2) = I1
−1 U1,overlap
T U2,overlapI2
−1 using only the rows of U1 and U2 that cor-
respond to the overlapping observations. From the estimated covariance matrix 
cov(θˆ1, θˆ2) we can obtain the covariance matrix of the common part cov(βˆ1, βˆ2) .
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abstract
The results of studies investigating the relationship of smoking with venous throm-
bosis are inconsistent. Therefore, in the MEGA study, a large population-based 
case-control study, we evaluated smoking as a risk factor for venous thrombosis 
and the joint effect with oral contraceptive use and the factor V Leiden mutation.
Consecutive patients with a first venous thrombosis were included from six an-
ticoagulation clinics. Partners of patients were asked to participate and additional 
controls were recruited using a random digit dialing method. Participants com-
pleted a standardized questionnaire. Individuals with known malignancies were 
excluded from the analyses, leaving a total of 3989 patients and 4900 controls.
Current and former smoking resulted in a moderately increased risk of venous 
thrombosis (odds ratio (OR)current 1.43, 95% confidence interval (CI95) 1.28-1.60, 
ORformer 1.23, CI95 1.09-1.38) compared to non-smoking. Adjustment for fibrino-
gen levels did not substantially change these risk estimates. A high number of pack-
years resulted in the highest risk among young current smokers (OR≥ 20 pack-years 
4.30, CI95 2.59-7.14) compared to young non-smokers. Women who were current 
smokers and used oral contraceptives had an 8.8-fold higher risk (OR 8.79, CI95 
5.73-13.49) than non-smoking women who did not use oral contraceptives. Rela-
tive to non-smoking non-carriers, the joint effect of factor V Leiden and current 
smoking led to a 5.0-fold increased risk; for the prothrombin 20210A mutation this 
was a 6.0-fold increased risk.
In conclusion, smoking appears to be a risk factor for venous thrombosis with 
the greatest relative effect among young women using oral contraceptives.
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introduction
Venous thrombosis is a common and serious disorder with acquired and genetic 
risk factors [1]. Several of these risk factors are common for arterial and venous 
thrombosis, e.g. oral contraceptive use [2]. Factors that promote atherosclerosis 
are thought not to have an effect on venous thrombosis. Smoking is directly related 
to vessel-wall damage [3], but may also increase the risk of cardiovascular disease 
through other mechanisms, such as inflammation and increased fibrinogen levels 
[4-9]. These may lead to arterial as well as venous thrombotic disease. Results of 
studies investigating the relationship between smoking and venous thrombosis are 
inconsistent and vary from an adverse to a protective effect of smoking. In the 
‘The Nurses Health Study’ a two-fold increased risk of pulmonary embolism was 
reported in women who smoked more than 35 cigarettes per day compared to never 
smokers [10]. ‘The Study of Men born in 1913’ reported a three-fold increased risk 
of venous thrombotic events in men smoking more than 15 cigarettes per day [11]. 
In contrast, The Framingham study showed that cigarette use had no association 
with pulmonary embolism found at autopsy [12]. A follow-up study of middle-
aged and elderly individuals also found no effect of smoking on venous thrombosis 
[13]. In a case-control study from France regular smoking was protective for deep 
venous thrombosis of the leg [14]. This finding may be explained by the nature of 
the control group that consisted of individuals with influenzal or rhinopharyngeal 
syndrome, i.e. which may have had an excess of smokers. The reason for the dis-
crepancy between the other study results is unclear.
A risk-increasing effect of smoking may be mediated through an increase in 
coagulation factors [8]. It is well known that smokers have higher fibrinogen lev-
els [5-9] and that smoking cessation causes a rapid fall in plasma fibrinogen [6]. 
Elevated levels of fibrinogen were related to the risk of venous thrombosis in the 
‘The Leiden Trombophilia Study’ (LETS), where we reported a 2.8-fold increased 
risk for individuals with fibrinogen levels above the 95th percentile (4.49 g/L) [15]. 
A case-control study among African-Americans found a 1.5-fold increased risk of 
venous thrombosis for fibrinogen levels above 5 g/L [16].
Since smoking is still common worldwide [17] it is important to address the 
contradictory study results and assess whether smoking affects the risk of venous 
thrombosis. In addition, the multicausal nature of venous thrombosis makes it im-
portant to investigate the effect of smoking in the presence of other risk factors. For 
arterial disease, smoking has been shown to act synergistically with oral contracep-
tive use [18]. Therefore we assessed the joint effect of smoking and oral contracep-
tive use on the risk of venous thrombosis. Factor V Leiden and the prothrombin 
mutation are the two most frequent prothrombotic mutations and are therefore 
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good candidates to investigate gene-environment interaction. To investigate the 
risk of venous thrombosis due to smoking, the possible role of fibrinogen in this 
relationship and the combination of smoking with oral contraceptive use, factor V 
Leiden and the prothrombin 20210A mutation, we performed a large population-
based case-control study.
methods
Study Design
Between March 1999 and September 2004, we included consecutive patients with 
a first diagnosis of venous thrombosis. Patients were selected from the files of the 
Anticoagulation Clinics in Amsterdam, Amersfoort, The Hague, Leiden, Rotterdam 
and Utrecht. In the Netherlands, Anticoagulation Clinics monitor anticoagulation 
treatment in all patients in a geographically well-defined area. Patients between the 
age of 18 and 70 with deep venous thrombosis of the leg, pulmonary embolism or a 
combination of these diagnoses were included. The diagnostic methods were veri-
fied in a random sample of the overall patient group (n=742). Within this group 
the diagnosis of 97% of deep venous thrombosis and 78% of pulmonary embolism 
had been objectively confirmed. The tests included compression ultrasonography, 
Doppler ultrasound, impedance plethysmography and contrastvenography for the 
diagnosis of deep venous thrombosis and perfusion and ventilation lung scanning, 
spiral computer tomography and pulmonary angiography for pulmonary embo-
lism.
Patients with severe psychiatric problems or those unable to speak Dutch were 
considered as ineligible. Of the 6331 eligible patients, 276 died soon after the 
venous thrombosis. Of the remaining 6055 patients 5051 participated (83%). Of 
the non-participants 82 persons were in the end stage of disease and 922 refused 
to participate or could not be located. Of the participants, 4637 (77%) patients 
returned the questionnaire. Participants who did not return a questionnaire com-
pleted a short questionnaire by phone, which did not include questions on smoking 
habits.
Partners of patients were asked to volunteer as control subjects. Of the 5051 
participating patients, 3657 had an eligible partner. One partner died soon after the 
request for participation. Of the remaining 3656 partners, 2982 participated (82%). 
Of the non-participants 18 were in end-stage disease, 649 refused to participate or 
could not be located and for seven persons the reason for non-participation was 
unknown. A questionnaire was returned by 2821 participating partners (77%).
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From January 2002 until September 2004, additional control subjects were re-
cruited by random digit dialing (RDD) [21]. Phone numbers were dialed at random 
within the geographical inclusion area of the patients. The random controls were 
frequency matched to the patients with respect to age and sex. Only control subjects 
between the age of 18 and 70 years with no history of deep venous thrombosis were 
included and the same exclusion criteria were applied as for the patients.
Of the 4350 eligible random control subject, four died before they were able to 
participate. Of the remaining 4346 persons 3000 participated (69%). Of the non-
participants 15 were in the end stage of disease and 1331 refused to participate or 
could not be located. A questionnaire was returned by 2789 participating random 
control subjects (64%).
All participants gave written informed consent. The study was approved by the 
Medical Ethics Committee of the Leiden University Medical Center, Leiden, The 
Netherlands.
Data collection
Within a few weeks after diagnosis and registration at the anticoagulation clinics 
patients received a letter with information about the study and were subsequently 
contacted by phone. Both patient and control subjects received the questionnaire 
shortly after inclusion. The questionnaires included items on smoking habits, body 
weight and body height, malignancies, pregnancies and use of oral contraceptives. 
Most questions referred to a period of 12 months prior to the index date, i.e. the 
date of diagnosis of the thrombosis of the patient for patients and partners and the 
date of filling in the questionnaire for the random control subjects.
When someone reported to smoke one cigarette per month or more the person 
was considered a smoker. Smokers were asked to report the age at which they 
started smoking, the age they quitted smoking, if there was a period in-between 
they did not smoke and the (cumulative) duration of such periods. Smokers were 
divided in current, former and never smokers. When the difference between the 
age at index date and the age of smoking cessation was 1 year or less, the person 
was considered a current smoker. The average number of cigarettes, self-rolled 
cigarettes, cigars or pipes smoked per day was also asked for. Because only a minor 
difference was found between different types of smoking and their risk of venous 
thrombosis, cigar and pipe smoking were included in the analysis by arbitrarily 
counting 1 cigar as 3 cigarettes and 1 pipeful as 2 ½ cigarettes. Several individuals 
wrote down the number of packages instead of the number of cigarettes smoked. 
In this case, the number of cigarettes was calculated with one package counted as 
20 cigarettes. For smokers of self-rolled cigarettes one package was counted as 50 
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cigarettes. Pack-years were defined as the average number of cigarettes per day 
divided by 20 and multiplied by the number of smoking years.
Individuals with malignancies diagnosed within 10 years before the index date 
(active malignancies) were excluded from all analyses. In addition, participants with 
missing data regarding items of the smoking questions, body weight and height or 
pregnancy were excluded from the analyses. In the analyses only partner controls 
with a participating patient were included, leading to a total of 3989 patients, 2288 
partner and 2612 random control subjects in the present analyses.
Blood collection
At least three months after withdrawal of anticoagulation the patients and their 
partners were asked to visit the anticoagulation clinic after an overnight fast and 
a blood sample was drawn. Only in case of continuous use for more than one year 
a blood sample was taken during anticoagulation therapy. From December 1999 
onwards, we obtained self-administered buccal swabs by mail when participants 
were unable or unwilling to come for a blood draw. From June 2002 onwards, blood 
draws were no longer performed in patients and their partners, and the study was 
restricted to DNA collection by buccal swabs sent by mail. The random controls 
were invited for a blood draw within a few weeks after the questionnaire was sent. 
Within this group buccal swabs were sent when someone refused the blood draw. 
During the blood draws information on smoking habits after the index date was 
obtained. In case of DNA collection by mailed buccal swabs a short interview was 
performed by phone.
Within the patient group 3745 provided a blood sample or buccal swab (94%). 
In the control subjects 4004 blood samples or buccal swabs were obtained (82%). 
Genotyping was successful in 3739 patients and 3983 control subjects for factor V 
Leiden and in 3739 patients and 3984 control subjects for the prothrombin 20210A 
mutation [22]. Fibrinogen levels were successfully determined in all blood samples, 
consisting of 2118 patient en 2485 control samples. Fibrinogen activity was mea-
sured according to the method of Clauss [23]. Calibration was performed using 
STA preciclot plus I en II. The intra-assay coefficient of variation (CV) was 1.81, 
the inter-assay CV was 3.78.
Statistical analysis
As estimates of relative risks we calculated odds ratios (ORs) and 95% confidence 
intervals (CI95) according to the method of Woolf [24]. With a multiple logistic 
regression model ORs were adjusted for age (continuous), sex (categorical), body 
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mass index (BMI=kg/m2) (continuous) and pregnancy (categorical). Adjustment 
for age (10 categories) and body mass index (8 categories) as categorical variables 
resulted in approximately the same risk estimates. In the analyses with partners as 
the control group, we performed a matched analysis to adjust for similar lifestyle 
factors between patients and their partners (2288 pairs) [25]. In the analyses with 
the random control subjects an unmatched analysis including all patients and 
random control subjects was performed. Because the results of the matched and 
unmatched analyses showed consistently elevated relative risks in all the analyses, 
we calculated pooled risk estimates with a method that combines the matched and 
unmatched analyses. This analysis takes into account the presence of 2288 patients 
in both the matched and unmatched analyses (see appendix chapter 2). When 
analyzing the risk in men and women separately it was not possible to perform 
a matched analysis with the partner controls, as control individuals were nearly 
always of the opposite sex. Therefore, risk estimates were calculated with an un-
matched analysis with all patients and the random control subjects.
In the analyses adjusted for fibrinogen levels (categorical), individuals who quit-
ted smoking after the index date but before the blood draw were included in the 
former smoking category. Individuals who started smoking in the period between 
the index date and the blood draw were included as current smokers. To further 
remove any effect of starters and quitters, we restricted an analysis adjusted for 
fibrinogen levels to individuals who consistently either smoked or did not smoke 
at the index date and the time of the blood draw. SAS 9.1 (SAS institute Inc, Cary, 
NC, USA) was used for all statistical analyses.
results
In these analyses data on 3989 patients and 4900 control subjects were included. 
Mean age of patients was 47.5 (5th-95th percentiles, 25.3-67.4) and of control sub-
jects 46.0 (5th-95th percentiles, 25.1-66.2) years old. Fifty five percent (n=2185) of 
patients and 53% (n=2606) of control subjects were women. In the patient group 
58% (n=2305) was diagnosed with deep venous thrombosis of the leg, 29% (n=1168) 
with pulmonary embolism and 13% (n=516) with the combination.
In table 1 relative risks of venous thrombosis with smoking status are presented. 
Among patients 37% was current and 28% was former smoker, in the control subjects 
32% was current and 28% was former smoker. Current and former smoking were 
both associated with a moderately increased risk of venous thrombosis compared 
with never smoking (ORcurrent 1.43, CI95 1.28-1.60, ORformer 1.23, CI95 1.09-1.38). 
The table presents the pooled odds ratios with both control groups. The effects 
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contrasting the patients to each control group separately did not materially differ 
from the pooled results (current smoking, partner controls OR 1.20, CI95 1.01-
1.44; current smoking, RDD controls OR 1.52, CI95 1.34-1.71; former smoking, 
partner controls OR 1.33, CI95 1.13-1.56; former smoking, RDD controls OR 1.17, 
CI95 1.03-1.33). To investigate causal mechanisms we adjusted the associations 
table i. Relative risk of venous thrombosis by smoking status
Smoking status Patients Partners RDD ORCombined
a 
(CI95)
ORCombined
b 
(CI95)
ORCombined
c
(CI95)
Never 1391 867 1109 1 1 1
Former 1136 665 692 1.23
(1.09-1.38)
1.20
(1.03-1.41)
1.22
(1.04-1.43)
Current 1462 756 811 1.43
(1.28-1.60)
1.40
(1.19-1.63)
1.34
(1.15-1.57)
RDD, random digit dialing controls; OR, odds ratio; CI, confidence interval.
aAdjusted for age, sex, BMI and pregnancy.
bAdjusted for age, sex, BMI and pregnancy in participants with measured fibrinogen levels (53% of 
patients, 50% of control subjects).
cAdjusted for age, sex, BMI, pregnancy and fibrinogen levels in participants with measured fibrinogen 
levels.
table ii. Relative risk of venous thrombosis by smoking status in different subgroups
Patients Control subjects ORa (CI95)
DVT
 Never 802 1976 1
 Former 642 1357 1.18 (1.02-1.36)
 Current 861 1567 1.50 (1.31-1.71)
PE
 Never 391 1976 1
 Former 349 1357 1.38 (1.15-1.64)
 Current 428 1567 1.53 (1.29-1.80)
DVT+PE
 Never 198 1976 1
 Former 145 1357 0.99 (0.78-1.27)
 Current 173 1567 1.21 (0.96-1.53)
All VTwomen
b
 Never 877 706 1
 Former 516 334 1.22 (1.02-1.46)
 Current 792 443 1.55 (1.33-1.82)
All VTmen
b
 Never 514 403 1
 Former 618 358 1.03 (0.85-1.26)
 Current 669 368 1.42 (1.18-1.71)
DVT, deep venous thrombosis; PE, pulmonary embolism; OR, odds ratio; CI, confidence interval; aadjusted 
for age, sex, BMI and pregnancy; bthree patients were not included in these analyses because two were 
transsexuals and one had Klinefelter syndrome, this analysis is performed using the random control 
subjects only
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for fibrinogen levels. We found slightly attenuated risk estimates after adjustment 
(table 1). Adjustment for fibrinogen in the analyses comparing consistent current 
smokers (at the index date and time of blood draw) to consistent non-smokers, 
resulted in only slightly lower risk estimates than before adjustment (ORcurrent 1.46, 
CI95 1.25-1.71; ORcurrent, adj 1.41, CI95 1.20-1.65).
For pulmonary embolism and deep venous thrombosis, current smoking resulted 
in the same relative risk (ORPE 1.53, CI95 1.29-1.80; ORDVT 1.50, CI95 1.31-1.71). 
Former smoking was associated with a higher relative risk of pulmonary embolism 
(OR 1.38, CI95 1.15-1.64) than of deep venous thrombosis (OR 1.18, CI95 1.02-
1.36) (table 2). Also, smoking increased the risk of thrombosis more in women 
than men.
In table 3 relative risks are presented for the number of cigarettes smoked per 
day and the number of smoking-years. In current smokers, daily amount smoked 
was associated with the risk of venous thrombosis in a dose-dependent manner. 
Smoking 20 or more cigarettes per day resulted in a 1.6-fold increased risk among 
current smokers compared to never smokers (OR 1.64, CI95 1.41-1.90). No dose 
table iii. Relative risk of venous thrombosis by number of cigarettes smoked per day and smoking period
Smoking amount (cigarettes/day) Patients Control subjects ORa (CI95)
Current
 never 1391 1696 1
 1-9 242 277 1.23 (1.00-1.50)
 10-19 524 528 1.41 (1.21-1.64)
 ≥ 20 676 589 1.64 (1.41-1.90)
Former
 never 1391 1781 1
 1-9 286 321 1.20 (1.00-1.45)
 10-19 372 400 1.22 (1.03-1.45)
 ≥ 20 444 474 1.08 (0.92-1.28)
Smoking period (years)
Current
 never 1391 1689 1
 1-9 162 166 1.54 (1.19-2.01)
 10-19 279 324 1.37 (1.13-1.67)
 ≥ 20 935 834 1.46 (1.27-1.67)
Former
 never 1391 1748 1
 1-9 226 243 1.33 (1.08-1.64)
 10-19 325 382 1.09 (0.91-1.31)
 ≥ 20 425 420 1.11 (0.93-1.32)
OR, odds ratio; CI, confidence interval; aadjusted for age, sex, BMI and pregnancy
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response relation was found for the number of smoking-years in either current or 
former smokers.
Table 4 shows the effects of the number of pack-years for three age categories 
in current smokers. In the youngest age category the risk of thrombosis increased 
with pack-years smoked, with a 4.3-fold increased risk for smokers with 20 or more 
pack-years (OR 4.30, CI95 2.59-7.14). In those aged over 38, we saw no association 
between pack-years and the risk of venous thrombosis.
We also investigated the joint effect of smoking with oral contraceptive use in 
women aged 18 to 39 years (table 5). Among non-users, smoking was associated 
with a 2.0-fold increased risk. Women who used oral contraceptives and did not 
smoke had a 3.9-fold increased risk, while those who also smoked had an 8.8-fold 
increased risk (compared to never smokers not using oral contraceptives).
Among non-carriers of factor V Leiden current smoking resulted in a 1.4-fold 
increased risk. The joint effect of factor V Leiden and current smoking resulted in 
a 5.0-fold increased risk compared to never smokers without the mutation (table 
6). For current smokers with the prothrombin 20210A mutation the risk of venous 
thrombosis increased 6.0-fold compared to never smokers without the mutation.
table iV. Relative risk of venous thrombosis by number of pack-years in three age categories (tertiles)
Pack-years ORa (CI95) ORa (CI95) ORa (CI95)
Current smokers < 37.8 yrs 37.8-51.1 yrs ≥ 51.1 yrs
 never 1 1 1
 1-9 1.38 (1.07-1.77) 0.94 (0.66-1.36) 1.25 (0.76-2.07)
 10-19 2.76 (1.99-3.83) 1.32 (0.97-1.79) 1.06 (0.71-1.59)
 ≥ 20 4.30 (2.59-7.14) 1.34 (1.05-1.72) 1.14 (0.91-1.42)
OR, odds ratio; CI, confidence interval; aadjusted for age, sex, BMI and pregnancy
Note: The pack-year analyses were performed in three different age categories because the number of 
pack-years was dependent on the age of the participants. We established the categories by dividing the 
age distribution of the current smokers into tertiles.
table V. Combined effect of smoking status with oral contraceptive (OC) use on the risk of venous 
thrombosis in women aged 18 to 39
Smoking status OC use Patients Control subjects ORa (CI95)
Never no 105 168 1
Former no 54 52 1.63 (1.00-2.67)
Current no 87 93 2.03 (1.33-3.11)
Never yes 257 189 3.90 (2.63-5.79)
Former yes 82 40 4.83 (2.89-8.08)
Current yes 271 94 8.79 (5.73-13.49)
OR, odds ratio; CI, confidence interval; aadjusted for age, BMI and pregnancy;
Note: The OC analyses were performed with random control subjects only
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discussion
In this large population-based case-control study smoking was associated with a 
moderately increased risk of venous thrombosis, in current and former smokers. 
In current smokers, who had the highest risk, the risk increased with the amount 
of smoking. This is in accordance with the results of two follow-up studies, ‘The 
Nurses Health Study’ and ‘The study of Men born in 1913’ [10,11]. These studies, 
as well as those that did not found an association [12,13], all included less than 700 
patients with venous thrombosis, while ours included almost 4000 patients.
We assessed the number of years someone had smoked, and found no association 
with thrombotic risk. It seems that the effect of smoking on venous thrombosis 
is largely an acute effect. This is illustrated by the presence of a dose response 
relationship between the amount of smoking and thrombotic risk in current smok-
ers. Furthermore this is supported by the absence of a dose response relationship 
for smoking duration, the higher risk estimates in current compared to former 
smokers and the finding of a dose response relationship with pack-years in young 
individuals only.
In our study, the risk estimates in the current smoking category may be somewhat 
underestimated, because we included persons who quit smoking up to one year 
before the index date in the current smoking group. In case people underreported 
the amount of smoking some non-differential misclassification may also have oc-
curred.
table Vi. Combined effect of smoking status with factor V Leiden (FVL) and the prothrombin (FII) 20210A 
mutation on the risk of venous thrombosis
Smoking status FVL Patients Control subjects ORa (CI95)
Never no 1085 1375 1
Former no 930 1017 1.21 (1.06-1.39)
Current no 1106 1048 1.43 (1.26-1.63)
Never yes 234 70 3.41 (2.53-4.58)
Former yes 161 41 3.76 (2.58-5.49)
Current yes 223 42 5.05 (3.46-7.38)
FII 20210A Patients Control subjects ORa (CI95)
Never no 1238 1517 1
Former no 1039 1111 1.21 (1.06-1.37)
Current no 1269 1168 1.41 (1.25-1.60)
Never yes 81 16 3.17 (1.94-5.18)
Former yes 52 11 3.01 (1.60-5.68)
Current yes 60 5 6.06 (2.67-13.76)
OR, odds ratio; CI, confidence interval; aadjusted for age, sex, BMI and pregnancy; Note: the inclusion of 
matched case control pairs in the analyses was dependent on the category (BMI, FVL; BMI, FII) of both 
individuals.
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Former smoking resulted in a more pronounced risk of pulmonary embolism 
than of deep venous thrombosis of the leg. This finding may reflect local inflamma-
tory effects in the lungs. The effect of smoking was also more pronounced in women 
than men. An explanation is our finding of a synergistic effect of smoking with oral 
contraceptive use, which is in accordance with the results of studies on myocardial 
infarction [18]. An evaluation of the effects of oral contraceptives on coagulation in 
smokers compared to non-smokers showed that changes in coagulation in women 
taking oral contraceptives were mainly evident in smoking women [19].
To investigate a mechanism for the association between smoking and venous 
thrombosis we adjusted our analyses for fibrinogen levels, hypothesizing that the 
risk was mediated via elevated fibrinogen levels. This adjustment, however, resulted 
only in slightly decreased risk estimates for current smoking, and therefore fibrino-
gen levels are not a crucial part of the mechanism. The question remains which 
other factors affected by smoking lead to the increased risk of venous thrombosis. 
A study that investigated the effect of smoking on the coagulation system found 
increased levels of factor VII, prothrombin, factor XI peptide and factor X peptide 
in smokers [8]. Besides coagulation factors, inflammatory factors may be involved. 
Interleukine-6 has been shown to be elevated in smokers [4] and is also associated 
with the risk of recurrent venous thrombosis [20].
Control subjects were drawn from two different sources. There were only minor 
differences when estimates were obtained with each control group separately. These 
differences are likely to be chance variations, although minor true differences can-
not be ruled out, possibly related to differences in non-response.
In conclusion, in this large population-based case-control study we found smok-
ing to be a moderate risk factor for venous thrombosis, that acts synergistically 
with oral contraceptive use. The joint effect of smoking with the factor V Leiden 
mutation or the prothrombin 20210A mutation was also slightly higher than the 
sum of the separate effects. Our findings suggest that fibrinogen levels are not an 
important mediator of the effect of smoking on the risk of venous thrombosis.
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summary
Moderate alcohol consumption is associated with lower levels of several coagulation 
factors. It is an established protective factor for cardiovascular disease; however the 
effect on venous thrombosis is unknown. In a large population-based case-control 
study, we evaluated the association between alcohol consumption and the risk of 
venous thrombosis.
The MEGA study included consecutive patients with a first venous thrombosis 
between March 1999 and September 2004 from six anticoagulation clinics in the 
Netherlands. Partners of patients were asked to participate and additional controls 
were recruited using a random digit dialing method. All participants completed 
a standardized questionnaire and blood samples were collected. A total of 4423 
patients and 5235 controls were included in the analyses.
Alcohol consumption was associated with a reduced risk of venous thrombosis, 
with two to four glasses per day resulting in the largest beneficial effect (Odds Ratio 
(OR) 0.67, 95% confidence interval (CI95) 0.58-0.77) compared to abstainers. The 
effect was more pronounced in women (OR 0.66, CI95 0.53-0.84) than men (OR 
0.82, CI95 0.63-1.07) and also more striking for pulmonary embolism (OR 0.56, 
CI95 0.46-0.70) than for deep venous thrombosis of the leg (OR 0.74, CI95 0.63-
0.88).
Compared to abstainers, fibrinogen levels were decreased in individuals who 
consumed alcohol (maximum decrease: 0.30 g/l). Factor VII and von Willebrand 
levels were mildly decreased in these individuals but not consistently over the 
categories of alcohol consumption.
In conclusion, alcohol consumption is associated with a reduced risk of venous 
thrombosis, which may be in part mediated by decreased fibrinogen levels.
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introduction
The protective effect of moderate and the harmful effect of heavy alcohol consump-
tion on the risk of arterial disease has been shown in many epidemiological studies 
(1). Similar effects of alcohol consumption on the risk of venous thrombosis are 
also not unlikely considering the effect of alcohol consumption on coagulation fac-
tors. A systematic review reported an association between moderate alcohol intake 
and reduced levels of fibrinogen, factor VII and von Willebrand factor, whereas 
heavy and binge alcohol drinking was associated with increased levels of fibrinogen 
and factor VII (2).
Few studies have reported on the relationship between alcohol consumption and 
venous thrombosis. In an Italian cohort study of elderly individuals low to moder-
ate alcohol consumption appeared beneficial with relative risks of 0.7 for less than 
one drink a month, 0.6 for less than one ounce per day and 0.5 for one or more 
than one ounce per day (3). In contrast, two US cohort studies found no effect of 
alcohol consumption on the risk of venous thrombosis (4, 5). In these cohort stud-
ies alcohol intake was only assessed at baseline and variations of alcohol intake 
during follow-up may have resulted in misclassification of alcohol levels and spu-
rious estimates. In a French case-control study no effect of alcohol consumption 
was found (6). In this study, the control group consisted of patients with influenzal 
or rhino pharyngeal symptoms in whom alcohol consumption may differ from 
the base population of cases. Alcohol is consumed regularly by 2 billion people 
worldwide (7), which makes it important to elucidate the relationship between 
alcohol consumption and the risk of venous thrombosis. In the Multiple Envi-
ronmental and Genetic Assessment of risk factors for venous thrombosis (MEGA 
study), a large population-based case-control study, we investigated alcohol use 
as a risk factor for venous thrombosis. In addition we analyzed the association of 
alcohol consumption with fibrinogen, factor VII and von Willebrand factor levels 
to verify if a protective effect could be explained by changes in these coagulation 
parameters.
methods
Study Design
Details of the MEGA study have been published (8). Between March 1999 and 
September 2004, consecutive patients with a first deep venous thrombosis of the 
leg or a pulmonary embolism were included from six anticoagulation clinics. 
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All patients were between the age of 18 and 70. Patients with severe psychiatric 
problems or those unable to speak Dutch were considered as ineligible. Partners 
of patients were asked to participate as control subjects. From January 2002 until 
September 2004, an additional control group was recruited using a random digit 
dialing method. Phone numbers were dialed at random within the geographical 
inclusion area of the patients. During the phone call a specific person within a 
household (e.g. youngest woman between 20 and 50) was asked to participate. The 
random control subjects were frequency matched to the patients with respect to 
age and sex. Only control subjects with no recent history of venous thrombosis 
were included and the same exclusion criteria applied as for the patients.
Among the 6055 eligible patients 5051 participated (83%). Of the 5051 partici-
pating patients, 3656 had an eligible partner of whom 2982 participated (82%). Of 
the 4346 eligible random control subjects 3000 participated (69%).
All participants gave written informed consent and the study was approved by 
the Medical Ethics Committee of the Leiden University Medical Center, Leiden, 
The Netherlands.
Data collection
Within a few weeks after diagnosis and registration at the anticoagulation clinics 
patients received a letter with information about the study and were subsequently 
contacted by phone. If the patient was willing to participate a questionnaire was 
sent. The control subjects received the questionnaires immediately after inclusion 
by phone. The questionnaire was returned by 4637 patients (77%), 2821 partners 
(77%) and 2789 random control subjects (64%). The participants who did not 
return a questionnaire were asked questions by phone. This short interview did not 
include questions regarding alcohol consumption.
The question referring to alcohol consumption included ten categories of alcohol 
consumption: none, 1 glass or less per week, 2 to 6 glasses per week, 1 glass per day, 
2 to 4 glasses per day, 5 to 9 glasses per day, 10 to 19 glasses per day, 20 to 29 glasses 
per day, 30 to 39 glasses per day and 40 or more glasses per day. Because only 85 
individuals filled in an amount in the highest four categories of alcohol consump-
tion these categories were taken together in the analysis. The questionnaire did not 
ask about kind of alcohol used. Participants who returned the questionnaire with 
missing data on alcohol consumption, body weight or height, smoking or preg-
nancy were excluded from all analyses. The total excluded proportion was the same 
in patients (4.6%) and control subjects (4.7%). In the analyses only partner controls 
with a participating patient were included leading to a total of 4423 patients, 2576 
partner and 2659 random control subjects for the present analyses.
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Blood collection
At least three months after withdrawal of anticoagulation the patients and their 
partners were asked to visit the anticoagulation clinic after an overnight fast where 
a blood sample was drawn. Only in case of continuous use for more than one year 
a blood sample was taken during anticoagulation therapy. From December 1999 
onwards, we obtained self-administered buccal swabs by mail when participants 
were unable or unwilling to come for a blood draw. From June 2002 onwards, blood 
draws were no longer performed in patients and their partners, and the study was 
restricted to DNA collection by buccal swabs sent by mail. The random controls 
were invited for a blood draw within a few weeks after the questionnaire was sent. 
Within this group buccal swabs were sent when someone refused the blood draw.
In the control subjects 2614 blood samples were obtained (50%). Fibrinogen, von 
Willebrand factor and factor VII were successfully determined in 2612 samples. 
Fibrinogen activity was measured on the STA-R analyzer according to methods 
of Clauss (9). The intra-assay coefficient of variation (CV) was 1.8, the inter-assay 
CV was 3.8. Factor VII activity (FVII) was measured with a mechanical clot detec-
tion method on the STA-R analyzer following the instructions of the manufac-
turer (Diagnostica Stago, Asnieres, France). The intra-assay CV was 3.4, the inter-
assay CV was 4.0. Von Willebrand factor antigen (vWF) was measured with the 
immuno-turbidimetric method, using the STA liatest kit (rabbit anti-human vWF 
antibodies), following the instructions of the manufacturer. For vWF the intra- and 
inter-assay CV were 3.6 and 2.6.
Statistical analysis
Odds ratios (OR) were calculated as estimates of the relative risk with 95% confi-
dence intervals (CI95) according to the method of Woolf. Using a multiple logistic 
regression model ORs were adjusted for age (continuous), sex (categorical), body 
mass index (BMI=kg/m2) (continuous), pregnancy (categorical) and smoking 
(categorical). Adjustment for age (10 categories) and body mass index (8 catego-
ries) as categorical variables resulted in approximately the same risk estimates. 
Additional adjustment for disease history, including malignancies, did not change 
the risk estimates. In the analyses with the random control subjects an unmatched 
analysis including 4423 patients and 2659 random control subjects was performed. 
In the analyses with partners as the control group (2576 pairs), we performed a 
matched analysis which adjusts for similar lifestyle factors between patients and 
their partners (10). Because the results of the matched and the unmatched analyses 
showed consistently protective relative risks in all analyses, we calculated pooled 
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risk estimates with a method that combines the matched and unmatched analyses 
(11). When analyzing the risk in men and women separately it was not possible to 
perform a matched analysis with the partner controls, therefore risk estimates were 
calculated with an unmatched analysis with all patients and the random control 
subjects.
A χ2-test was used to compare alcohol consumption between patients with deep 
venous thrombosis of the leg with those in patients with a pulmonary embolism.
SAS 9.1 (SAS institute Inc, Cary, NC, USA) was used for all statistical analyses.
results
In the current analysis 4423 patients with a first venous thrombosis and 5235 control 
subjects were included. Mean age of the patients was 48.5 years (5th-95th percentiles, 
25.8-67.7) and the control subjects were on average 46.8 years (5th-95th percentiles, 
25.4-66.4). In the patient and in the control group 54% were women (npatient=2400, 
ncontrol=2816). In the patient group 57% (n=2528) was diagnosed with deep venous 
thrombosis of the leg, nearly a third (n=1340) with pulmonary embolism and 13% 
(n=555) with the combined diagnosis of deep venous thrombosis and pulmonary 
embolism.
Figure 1 shows the relationship between alcohol consumption and the risk of ve-
nous thrombosis. Moderate alcohol consumption was associated with a decreased 
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Figure 1. Relative risk of venous thrombosis by level of alcohol consumption
*adjusted for age, sex, body mass index, smoking and pregnancy;
I, CI95; np, number of patients; nc, number of control subjects;
ref., reference category
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risk of venous thrombosis, with two to four glasses per day resulting in the 
strongest effect on the risk of venous thrombosis (OR2-4/day 0.67, CI95 0.58-0.77) 
compared to abstainers. Even drinking more than four glasses per day appeared to 
be still somewhat protective (OR5-9/day 0.82, CI95 0.65-1.04, OR≥10/day 0.71, CI95 
0.45-1.12). Moderate alcohol consumption was associated with a somewhat more 
decreased risk for women (OR2-4/day 0.66, CI95 0.53-0.84) than men (OR2-4/day 0.82, 
CI95 0.63-1.07).
The associations of alcohol consumption with the risk of deep venous thrombosis 
and pulmonary embolism separately are presented in figure 2. The protective effect 
of alcohol consumption appeared to be more pronounced for the diagnosis of pul-
monary embolism (OR2-4/day 0.56, CI95 0.46-0.70) than for deep venous thrombosis 
(OR2-4/day 0.74, CI95 0.63-0.88). Drinking two glasses per week or more clearly 
protected more against pulmonary embolism than against deep venous thrombosis 
(P=0.02).
In figure 3 mean fibrinogen, factor VII and von Willebrand factor levels are pre-
sented for different categories of alcohol consumption in control subjects. Alcohol 
consumption categories which were associated with the most pronounced reduction 
in venous thrombotic risk were also associated with reduced levels of fibrinogen. 
Factor VII levels and von Willebrand factor levels were also lower in drinkers than 
non-drinkers, but there were no consistent patterns over the categories of alcohol 
consumption.
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Figure 2. Relative risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) by level of alcohol 
consumption
*adjusted for age, sex, body mass index, smoking and pregnancy;
I, CI95; ref., reference category
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discussion
In this large case-control study moderate alcohol consumption was associated with 
a decreased risk of venous thrombosis. This potential beneficial effect of moderate 
alcohol consumption appeared to be more pronounced in women than men and 
for pulmonary embolism than for deep venous thrombosis of the leg.
Very little is known about the mechanisms by which alcohol may exert anti-
thrombotic effects. Some studies have shown that moderate alcohol consumption 
is associated with a more favorable coagulation profile, indicated by lower levels of 
fibrinogen, factor VII and von Willebrand factor (12, 13). In accordance with these 
studies we found reduced levels of fibrinogen, factor VII and von Willebrand factor 
in moderate alcohol drinkers. Reduced levels were most striking for fibrinogen, 
where levels were even decreased up to high levels of alcohol consumption (5-9 
glasses per day).
The difference between men and women in the alcohol-related risk of venous 
thrombosis may be explained by the differential effects of wine and beer (14), the 
latter of which is consumed more by men than women. Unfortunately, in our study 
we had no information about the kind of alcoholic drinks the participants con-
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Figure 3. Mean levels of haemostatic variables according to alcohol consumption in control subjects
I, standard error of the mean
N=2612
59
Alcohol consumption and venous thrombosis
c
h
ap
te
r 
4
sumed. A question about type of alcoholic drinks could have provided important 
additional information. A recent study however, showed that wine, beer and spirits 
were to the same extend protective for myocardial infarction, suggesting that type 
of alcohol drink did not influence the effect (15).
It was striking that the protective effect of drinking two or more glasses of alcohol 
per week was higher for pulmonary embolism than for deep venous thrombosis of 
the leg. We do not have an explanation for these findings.
A limitation of our study is that alcohol consumption was self-reported. Although 
it is possible that individuals underreport alcohol consumption, this is mainly a 
problem when there is a difference between patients and control subjects in report-
ing behavior. If patients and controls both had underreported, the protective effect 
we observed was underestimated. If patients underreported more than controls, 
the true effect would have been less pronounced. The proportion of individuals 
who failed to report their alcohol consumption was the same in patients (0.71%) 
and controls (0.66%), which suggests that the two groups behaved similarly in 
answering this question.
In conclusion, in this large population-based case-control study alcohol con-
sumption is associated with a decreased risk of venous thrombosis, with two to 
four glasses per day resulting in the largest effect. This effect may be mediated by a 
decrease in coagulation factors, especially fibrinogen.
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summary
Background: Venous thrombosis is one of the leading causes of maternal morbidity 
and mortality.
Objective: In the MEGA study, we evaluated pregnancy and the postpartum pe-
riod as risk factors for venous thrombosis in 285 patients and 857 control subjects. 
Patients/Methods: Between March 1999 and September 2004, consecutive patients 
with a first episode of venous thrombosis were included from six anticoagulation 
clinics. Partners of patients and a random digit dialing group were included as 
control subjects. Participants completed a questionnaire and DNA was collected.
Results: The risk of venous thrombosis was five-fold (OR 4.6, 95%CI 2.7-7.8) 
increased during pregnancy and sixty-fold (OR 60.1, 95%CI 26.5-135.9) increased 
during the first three months after delivery compared to non-pregnant women. A 
14-fold increased risk of deep venous thrombosis of the leg was found compared 
to a six-fold increased risk of pulmonary embolism. The risk was highest in the 
third trimester of pregnancy (OR 8.8, 95%CI 4.5-17.3) and during the first six 
weeks after delivery (OR 84.0, 95%CI 31.7-222.6). The risk of pregnancy-associated 
venous thrombosis was 52-fold increased in factor V Leiden carriers (OR 52.2, 
95%CI 12.4-219.5) and 31-fold increased in carriers of the prothrombin 20210A 
mutation (OR 30.7, 95%CI 4.6-203.6) compared to non-pregnant women without 
the mutation.
Conclusion: We found an increased risk of venous thrombosis during pregnancy 
and the postpartum period, with an especially high risk during the first six weeks 
postpartum. The risk of pregnancy-associated venous thrombosis was highly in-
creased in carriers of factor V Leiden or the prothrombin 20210A mutation.
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introduction
Venous thrombosis is one of the leading causes of maternal morbidity and mortal-
ity1, 2. In developed countries, about 15% of maternal deaths results from pulmo-
nary embolism3. In women of reproductive age, over half of all venous thrombotic 
events are related to pregnancy4.
A large study of pregnancy associated venous thrombosis is the Glasgow study, 
a retrospective study of over 72000 deliveries5. This study reported an incidence 
of pregnancy-associated venous thrombosis of 3.24 per 1000 women years, with 
an incidence of 2.45 per 1000 women years for deep venous thrombosis of the 
leg and an incidence of 0.79 per 1000 women years for pulmonary embolism. For 
deep venous thrombosis of the leg the majority of cases (84%) occurred in the left 
leg, which is in accordance with the findings of other studies6, 7. The mechanism 
behind this propensity for the left leg is still under debate8. During pregnancy, the 
risk was highest during the third trimester5. Findings of other studies addressing 
risk differences in the three trimesters of pregnancy are inconsistent. An equal risk 
distribution during all three trimesters of pregnancy has been reported but there 
are also studies showing the highest risk during the first or second trimester of 
pregnancy6-10. The incidence of thrombosis was highest during the first six weeks 
after delivery both for deep venous thrombosis of the leg and for pulmonary em-
bolism5. A higher risk during the postpartum period compared to pregnancy is 
reported by many other studies10, 11.
As women with thrombophilia are at increased risk of venous thrombosis, a num-
ber of studies have been carried out to study the effect of pregnancy and the post-
partum period in these women12-17. The most common inherited thrombophilias 
are the factor V Leiden and the prothrombin 20210A mutation. A meta-analysis 
of thrombophilias in pregnant women has shown the risk to be over eight-fold 
higher for heterozygous factor V Leiden carriers and almost seven-fold higher for 
heterozygous prothrombin 20210A mutation carriers than in pregnant women 
without thrombophilia18.
In the Multiple Environmental and Genetic Assessment of risk factors for venous 
thrombosis (MEGA study), a large population-based case-control study, we evalu-
ated pregnancy and the postpartum period as risk factors for venous thrombosis. 
We were able to identify a sufficient number of patients in their pregnancy or 
postpartum period to allow for subgroup analyses; we evaluated the pregnancy-
associated risk of deep venous thrombosis of the leg and pulmonary embolism 
separately and also analysed the risk of specific time frames within the pregnant 
and postpartum period. In addition the joint effect of pregnancy with factor V 
Leiden and the prothrombin 20210A mutation was addressed.
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methods
Participants
The MEGA study included consecutive patients with a first diagnosis of venous 
thrombosis. Between March 1999 and September 2004, patients were recruited from 
six regional anticoagulation clinics (Amersfoort, Amsterdam, Den Haag, Leiden, 
Rotterdam and Utrecht) which monitor the anticoagulant therapy of all patients 
within a well-defined geographical area in the Netherlands. In order to participate, 
patients were required to be between the age of 18 and 70. Patients with severe 
psychiatric problems or those unable to speak Dutch were for practical reasons 
considered ineligible. Within the total patient group the diagnosis of 97% of deep 
venous thrombosis and 79% of pulmonary embolism was objectively confirmed. 
Ninety percent of patients used in the final analysis had an objectively confirmed 
diagnosis. Seven out of 285 patients (2.5%) had no objectively confirmed diagnosis 
and twenty-one out of 285 patients did not provide permission to obtain their 
medical records (7.4%). The tests included compression ultrasonography, Doppler 
ultrasound, impedance plethysmography and contrast venography for diagnosis 
of deep venous thrombosis and perfusion and ventilation lung scanning, spiral 
computer tomography and pulmonary angiography for pulmonary embolism.
Partners of patients were asked to participate as control subjects and an additional 
control group was obtained using the random digit dialing (RDD) method19. Only 
control subjects with no recent history of venous thrombosis were included and 
the same exclusion criteria as for patients were applied. Details of the MEGA study 
have been published previously20.
Of 6055 eligible patients, 5051 participated (83%). Within this group 2737 were 
women and 2714 provided information on whether they had been pregnant or 
not before the thrombotic event. Of the 5051 participating patients, 3656 had an 
eligible partner of whom 2982 participated (82%). An additional 314 partners 
were included of whom the patient was either excluded for the final analysis, or 
had deep venous thrombosis of the arm. Thus a total of 3298 partners were will-
ing to participate. Within this group 1665 were women of whom 1645 provided 
pregnancy related information. Out of 4350 eligible RDD control subjects, 3000 
were willing to participate (69%). Information on pregnancy was obtained from 
1710 out of 1719 women in this group. Individuals who were over 50 years of age, 
had no partner, used oral contraceptives or hormone replacement therapy or had 
malignancy or a partner with malignancy (for patients and partner controls) were 
excluded from the analyses leading to 285 patients and 857 control subjects.
67
Pregnancy and venous thrombosis
c
h
ap
te
r 
5
The study was approved by the Medical Ethics Committee of the Leiden Univer-
sity Medical Center, the Netherlands. Written informed consent was obtained from 
all participants.
Data collection
Participants completed a detailed questionnaire on risk factors for venous throm-
bosis. Items covered in the questionnaire included oral contraceptive use, hormone 
replacement therapy, pregnancies, malignancies and civil status. The questionnaire 
covered a one year period prior to the index date, i.e. the date of diagnosis of the 
thrombosis for patients and the date of filling in the questionnaire for partners and 
the random control subjects. When participants were not willing to or unable to fill 
in the questionnaire, a standardized mini-questionnaire was taken by telephone, 
which also included pregnancy related questions. Participants were asked if they 
had been pregnant in the year before the index date or if they were still pregnant, 
and what the (expected) date of delivery was. We defined postpartum as the period 
up to three months after delivery. Information on the location of the affected leg in 
patients with a deep venous thrombosis of the leg was retrieved from the question-
naire and discharge letters. Out of 285 patients, 176 had a deep venous thrombosis 
of the leg (with or without pulmonary embolism) of whom 173 had information 
regarding the affected leg.
DNA collection
Three months after discontinuation of anticoagulant therapy patients and partner 
controls were invited for an interview and blood draw. In patients who continued 
anticoagulant therapy for over a year after the event, blood was drawn during anti-
coagulant therapy. When the participant was unable to come to the clinic a buccal 
swab was sent. From June 2002 onwards, blood draws were no longer performed 
in patients and their partners and blood draws were replaced by buccal swabs. 
Upon completion of the questionnaire, RDD controls were invited for an interview 
and blood draw. A detailed description of blood collection and DNA analysis for 
the factor V Leiden (G1691A) and the prothrombin mutation (G20210A) in the 
MEGA study has been published previously20.
Within the patient group used for the present analyses 256 provided a blood 
sample or buccal swab (90%). In the control group 681 blood samples or buccal 
swabs were obtained (79%). Factor V Leiden and the prothrombin 20210A muta-
tion were successfully determined in all patients and 679 control subjects.
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Statistical analysis
As estimates of relative risks odds ratios (ORs) and 95% confidence intervals 
(95%CI) were calculated according to the method of Woolf. With a multiple logis-
tic regression model we adjusted for age (categorical, seven classes). Because none 
of the control subjects in the analysis were matched to patients (they were either 
random population controls or partners of other (male) patients) all analyses were 
unmatched, with unconditional logistic regression. SPSS for Windows version 
12.0.1 (SPSS Inc, Chicago, Ill) was used for all statistical analyses.
results
A group of 285 women aged 18 to 50 with venous thrombosis and 857 control 
subjects in the same age group were included in the analysis, with a mean age of 
respectively 38.3 (5th -95th percentile, 25.7-49.6) and 39.9 years (5th -95th percentile, 
27.0-49.8). In the patient group 55% (n=158) was diagnosed with a deep venous 
thrombosis of the leg, 38% (n=109) with a pulmonary embolism and 6% (n=18) 
with the combined diagnosis.
Within the patient group, 116 out of 285 women (41%) were pregnant at the time 
of thrombosis or had been pregnant the three months before the thrombosis, com-
pared to 82 out of 857 (9.6%) control subjects at the index date. The risk of venous 
thrombosis was five-fold (OR 4.6, 95%CI 2.7-7.8) increased during pregnancy and 
sixty-fold (OR 60.1, 95%CI 26.5-135.9) increased during the first three months 
after delivery compared to non-pregnant women (Table 1).
Odds ratios were higher in young women than in older women: in women aged 
18 to 29 the risk of venous thrombosis during pregnancy was almost thirteen-fold 
increased (OR 12.5, 95%CI 4.0-39.5) whereas in women aged 30 to 50 the risk was 
three-fold increased (OR 3.3, 95%CI 1.8-6.1). Postpartum the risk was also more 
pronounced in women age 18 to 29 (OR 299.3, 95%CI 49.4-1813.1) than in women 
aged 30 to 50 (OR 29.4, 95%CI 12.1-71.5) (Table 1).
The risk of venous thrombosis during the first two trimesters of pregnancy ap-
peared to be only slightly increased, with an odds ratio of 1.6. However, the risk was 
increased nine-fold (OR 8.8, 95%CI 4.5-17.3) during the third trimester compared 
to non-pregnant women. During the first six weeks after delivery the risk was highest 
(OR 84.0, 95%CI 31.7 – 222.6). Most cases of venous thrombosis during this period 
occurred within the first four weeks (95%), with the highest number of cases in the 
second week (42%) compared to 18%, 20% and 15% in the first, third and fourth 
week. The risk remained increased up to three months postpartum (Table 2).
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Overall pregnancy associated risk was most pronounced for deep vein throm-
bosis of the leg (OR 14.3; 95%CI 8.3-24.5) and six-fold increased for pulmonary 
embolism (OR 5.8; 95%CI 3.3-10.3. During pregnancy, the risk of deep venous 
thrombosis of the leg was clearly increased (OR 7.8; 95%CI 4.1-15.0), whereas that 
of pulmonary embolism was at most weakly increased (OR 2.3; 95%CI 1.0-5.2). In 
the postpartum period the risk for both was increased, with a relative risk of 72.6 
for deep venous thrombosis of the leg and a relative risk of 34.4 for pulmonary 
embolism (Table 3).
The majority of pregnancy-associated deep venous thrombosis cases occurred in 
the left leg. During pregnancy 85% of women (23 out of 27) had a left-sided deep 
venous thrombosis, compared to 68% (32 out of 47) of women in the postpartum 
table 1. Relative risk of venous thrombosis during pregnancy and postpartum; overall and by age 
category
Age group
(yrs)
Status Patients (n) Control subjects (n) OR* 95%CI
18 to 50 Neither 169 775 1 Ref.
Pregnant† 36 58 4.6 2.7-7.8
Postpartum‡ 69 10 60.1 26.5-135.9
Overall§ 116 82 9.7 6.4-14.9
18 to 29 Neither 7 86 1 Ref.
Pregnant 14 18 12.5 4.0-39.5
Postpartum 34 3 299.3 49.4-1813.1
30 to 50 Neither 162 689 1 Ref.
Pregnant 22 40 3.3 1.8-6.1
Postpartum 35 7 29.4 12.1-71.5
Ref., Reference category; OR, odds ratio; 95%CI, 95% confidence interval
*adjusted for age
†four women who currently were and had previously been pregnant are included in the pregnant group
‡period up to 3 months after delivery §included the pregnant and postpartum category and an additional 
11 cases and 14 control subjects of whom delivery dates were unavailable
table 2. Relative risk of venous thrombosis by different stages of pregnancy and postpartum
Status Patients Control subjects OR* 95%CI
n (%) n (%)
Neither 167 60.9 735 87.2 1 Ref.
1st and 2nd trimester 8 2.9 36 4.3 1.6 0.7-3.7
3rd trimester 28 10.2 22 2.6 8.8 4.5-17.3
1 to 6 weeks postpartum 66 24.1 6 0.7 84.0 31.7-222.6
7 weeks to 3rd month postpartum 3 1.1 4 0.5 8.9 1.7-48.1
4th month to 1 year postpartum 2 0.8 40 4.7 0.3 0.1-1.4
Ref., Reference category; OR, odds ratio; 95%CI, 95% confidence interval
*adjusted for age
Note: Information on delivery dates was unavailable for 11 cases and 14 controls
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period. In women who were not pregnant the right-left distribution was almost even, 
with 53% (52 out of 99) diagnosed with a left-sided deep venous thrombosis.
Among non-carriers of factor V Leiden, pregnancy and the postpartum period 
resulted in a nine-fold increased risk of venous thrombosis (OR 8.6, 95%CI 5.2-
14.3). The joint effect of factor V Leiden and pregnancy resulted in a 52-fold 
table 3. Risk of deep venous thrombosis, pulmonary embolism and the combined diagnosis by 
pregnancy status
Patients (n) Control subjects (n) OR* 95%CI
DVT
 Neither 83 775 1 Ref.
 Pregnant 27 58 7.8 4.1-15.0
 Postpartum 42 10 72.6 30.1-175.4
Overall† 75 82 14.3 8.3-24.5
PE
 Neither 73 775 1 Ref.
 Pregnant 9 58 2.3 1.0-5.2
 Postpartum 22 10 34.4 13.3-88.5
Overall‡ 36 82 5.8 3.3-10.3
DVT+PE
 Neither 13 775 1 Ref.
 Pregnant 0 58 -- --
 Postpartum 5 10 46.4 10.0-214.7
Overall§ 5 82 5.5 1.4-21.1
DVT, deep venous thrombosis of the leg; PE, pulmonary embolism; Ref., Reference category; OR, odds 
ratio ; 95%CI, 95% confidence interval; *adjusted for age
†included the pregnant and postpartum category and an additional 6 cases and 14 control subjects of 
whom delivery dates were unavailable
‡included the pregnant and postpartum category and an additional 5 cases and 14 control subjects of 
whom delivery dates were unavailable
§included the pregnant and postpartum category and an additional 14 control subjects of whom delivery 
dates were unavailable
table 4. The joint effect of pregnancy status and the factor V Leiden mutation (FVL) or the prothrombin 
20210A (FII) mutation
Pregnant or 
postpartum
FVL Patients (n) Control subjects (n) OR* 95%CI
- - 144 580 1 Ref.
+ - 81 56 8.6 5.2-14.3
- + 12 40 1.3 0.6-2.5
+ + 19 3 52.2 12.4-219.5
FII
- - 141 605 1 Ref.
+ - 94 57 10.1 6.2-16.4
- + 15 15 4.4 2.1-9.4
+ + 6 2 30.7 4.6-203.6
Ref., Reference category; OR, odds ratio; 95%CI, 95% confidence interval
*adjusted for age
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increased risk (OR 52.2, 95%CI 12.4-219.5), compared to non-carriers who had 
not been pregnant (Table 4). The risk of pregnancy-associated venous thrombosis 
was 31-fold increased (OR 30.7, 95%CI 4.6-203.6) in carriers of the prothrombin 
20210A mutation, compared to non-pregnant, non-carriers (Table 4).
discussion
In this population-based case-control study we found a five-fold increased risk 
of venous thrombosis during pregnancy and a sixty-fold increased risk of venous 
thrombosis in the postpartum period. The risk was especially high during the first 
six weeks after delivery. The risk of both deep venous thrombosis of the leg and 
pulmonary embolism was increased during pregnancy and the postpartum period. 
During pregnancy venous thrombosis occurred far more often in the left than in 
the right leg. In carriers of the factor V Leiden mutation the risk of pregnancy-
associated venous thrombosis increased markedly to about 52-fold compared to 
non-carriers who had not been pregnant. A somewhat lower increase in risk was 
found in prothrombin 20210A carriers, in whom the risk was 31-fold increased, 
compared to non-carrying, non-pregnant women.
Our finding of a five-fold increased risk in women who were pregnant is in accor-
dance with the results of other studies10, 11. The higher relative risks of pregnancy in 
younger women compared to older women were in contrast with previous follow-
up studies. However, one should bear in mind the difference between relative and 
absolute risks. Since thrombosis is age-dependent, these two will never both be 
constant over age, and a similar absolute increase will lead to much higher relative 
risks in young than in older women. Hence, one cannot conclude from our data 
that the influence is lower in older than in younger women and the reverse is prob-
ably true, also based on these data.
While previous reports were conflicting about the risk per trimester of pregnan-
cy6-10, we found the highest risk during the third trimester. These findings should 
be interpreted with some caution, because the higher risk during the third trimes-
ter might reflect a relatively high number of misdiagnoses in this trimester due to 
compression issues by the gravid uterus that leads to symptoms similar to venous 
thrombosis8. However, this is not very likely in our study, since 97% of patients 
with deep venous thrombosis were objectively diagnosed. A more important con-
sideration is the inclusion of patients through anticoagulation clinics. Some women 
with venous thrombosis during pregnancy are initially treated without involvement 
of the anticoagulation clinic and receive low molecular weight heparin (LMWH). 
Women who had their venous thrombosis during the first or second trimester are 
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more likely to be treated with LMWH only than women with a venous thrombosis 
during the third trimester, who are referred to the anticoagulation clinic for ad-
ditional treatment after child delivery. This might have led to an underestimate of 
the risk of thrombosis during early stages of pregnancy, thus no firm conclusion 
can be drawn about lower risks in the first two trimesters compared with the third 
trimester.
The risk of venous thrombosis during the first six weeks after delivery was very 
high compared to the overall pregnancy-associated risk. Our finding of a 84-fold 
higher risk during this period is within the range of findings from the majority of 
other studies, that reported a two- to fifteen-fold increased risk during the first 
six weeks after delivery compared to pregnancy7, 14, 21. The Glasgow study found 
2.51 cases of venous thrombosis per 1000 person years in the first six weeks after 
delivery5. When we contrast this figure to the baseline risk of venous thrombosis 
of 0.08 per 1000 in these young women22, these data point to a relative risk of 31 
during this period. A case-control study in which control subjects were subject 
to the same referral and diagnostic procedures as patients found, however, less 
difference in the thrombotic risks during the first month after delivery and preg-
nancy23. A high risk of venous thrombosis during the first weeks after delivery may 
be explained by coagulation changes due to operative delivery, postnatal infections 
or immobility24.
For a correct calculation of relative risks during different stages of pregnancy 
and the postpartum period it is important that the proportion of control subjects 
in each time frame is a good reflection of the source population. To verify this, 
we calculated the expected number of controls in each period, using data from 
the general population25. The percentage of pregnant or postpartum women was 
higher in the random digit dialing control group (12.3%) than in the partner 
control group (3.8%). In the overall control group the prevalence of pregnant or 
postpartum women (8.1%) was similar to the general population (8.8%). During 
pregnancy the proportion of controls was similar to what we would expect to find 
(6.9% compared to an expected 6.6%). In the first three months postpartum we 
observed a lower proportion of controls (1.2% compared to an expected 2.2%), 
possibly due to a reduced motivation to participate in our study after child deliv-
ery. In the period from four months up to one year postpartum the proportion of 
controls was still somewhat reduced (4.7% compared to an expected 6.6%). These 
lower proportions have probably resulted in a slight overestimation of relative risks 
in the postpartum period.
Furthermore, the time needed for control subjects to return the questionnaire 
could have influenced the percentage of pregnant controls assigned to each period. 
As controls returned the questionnaire more quickly than patients and 61% of the 
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controls had replied within a week (86% within a month) this is unlikely to have 
affected results.
Not much is known about the relative risks of the separate diagnoses of deep ve-
nous thrombosis of the leg and pulmonary embolism, during and after pregnancy. 
An American cohort study reported an increased risk of deep venous thrombosis 
and pulmonary embolism during pregnancy. Postpartum the risks were further 
increased with a four-fold higher risk of deep venous thrombosis and a 15-fold 
increased risk of pulmonary embolism compared to the pregnant period10. Also 
a Danish cohort study reported an increased risk of both deep venous thrombosis 
and pulmonary embolism during pregnancy and the first six weeks after delivery, 
with again a higher risk of pulmonary embolism during the postpartum period 
compared to the pregnant period26. We found increased risks of deep venous 
thrombosis of the leg and pulmonary embolism postpartum, while during preg-
nancy the risk of pulmonary embolism was only slightly increased.
When analysing the combined effect of pregnancy and the postpartum pe-
riod with the factor V Leiden mutation or the prothrombin 20210A mutation, 
we found substantial increased risks for the combination of these risk factors. A 
meta-analysis of thrombophilias in pregnancy has found an eight-fold higher risk 
for heterozygous factor V Leiden carriers and an almost seven-fold higher risk 
for heterozygous prothrombin 20210A mutation carriers than pregnant women 
without thrombophilia18. Performing our analysis within pregnant women only, 
we found a five-fold increased risk for factor V Leiden carriers and a two-fold 
increased risk for prothrombin 20210A carriers.
In these young women, we found a low relative risk of 1.3 in carriers of fac-
tor V Leiden who had not been pregnant, which is lower than the overall risk of 
venous thrombosis due to factor V Leiden (three- or more fold increased)27. To 
investigate if the low risk was due to a too large proportion of non-pregnant factor 
V Leiden carriers among control subjects, we calculated the relative risk of venous 
thrombosis that one would expect in these control subjects using data from the 
general Dutch population as control situation. Using general data on live birth, 
stillbirth and use of oral contraceptives we calculated that 8.8% of these young 
women were expected to be pregnant or in the postpartum period25. Together with 
a prevalence of 5% for factor V Leiden28, the calculated relative risk would be 1.5 in 
carriers of factor V Leiden compared to non-carriers who had not been pregnant; a 
similar relative risk as our finding (with 144 patients of the reference category and 
the 12 non-pregnant patients with factor V Leiden the following calculation was 
performed: 144*(5*(1-0.088)/95*(1-0.088))=7.76, 12/7.76=1.5).
We performed several subgroup analyses with relatively small numbers of pa-
tients and control subjects. Several confidence intervals were wide, but results were 
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in accordance with previous studies and the lower boundaries of many confidence 
intervals were above 2.1, with odds ratios of 4.4 or higher, indicating that the true 
effects were likely to be substantial.
A limitation of our study was the absence of data on the mode of delivery. It 
would have been interesting to investigate if we could replicate or refute previous 
findings that reported an increased risk of venous thrombosis from vaginal delivery 
to elective caesarean section to emergency caesarean section2.
In conclusion, we found an increased risk of venous thrombosis during both 
pregnancy and the postpartum period, with an especially high risk during the 
first six weeks after delivery. Women with either factor V Leiden or prothrombin 
20210A thrombophilia had a substantially increased risk of pregnancy-associated 
venous thrombosis compared to women without these mutations.
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summary
Background/Objectives: Protein C is an important inhibitor of blood coagulation. 
We investigated the effect of two polymorphisms within the promoter region of the 
protein C gene (C/T at -2405 and A/G at -2418) on risk of venous thrombosis and on 
plasma protein C levels. In addition the combined effect of the two polymorphisms 
with factor V Leiden and oral contraceptive use was investigated. Previous studies 
on these polymorphisms were small and were not able to investigate synergistic 
effects.
Patients/Methods: In the Multiple Environmental and Genetic Assessment of 
risk factors for venous thrombosis (MEGA study), protein C levels were deter-
mined in 2043 patients with venous thrombosis and 2857 controls, and the two 
polymorphisms in 4285 patients and 4863 controls.
Results: The CC/GG genotype was associated with the lowest protein C levels. 
Compared to carriers of the TT/AA genotype - a genotype associated with higher 
protein C levels - the risk of venous thrombosis in CC/GG carriers was 1.3-fold 
increased (CI95 1.09-1.48). The combination of factor V Leiden with the CC/GG 
genotype led to a 4.7-fold increased risk, compared to non-carriers with the TT/
AA genotype. Oral contraceptive use together with the CC/GG genotype resulted 
in a 5.2-fold increased risk.
Conclusions: The CC/GG genotype is associated with lower levels of protein C 
and an elevated risk of venous thrombosis compared to the TT/AA genotype. There 
is no clear synergistic effect of the CC/GG genotype with factor V Leiden or oral 
contraceptive use on thrombotic risk.
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introduction
Activated protein C is a vitamin-K dependent natural anticoagulant. The antico-
agulant effect of protein C is a result of the selective inactivation of coagulation 
factors V and VIII, with protein S serving as a cofactor1.
The crucial role of protein C as an anticoagulant has been shown in many studies. 
Patients born with a homozygous protein C deficiency often have a severe form of 
thrombosis, called purpura fulminans2. In the early 1980s, several studies showed 
that heterozygous deficiencies, with fifty percent reduced protein C levels resulted 
in an increased risk of venous thrombosis3-5. Many families have been reported 
in the literature with recurrent thrombotic events due to this type of protein C 
deficiency7. More recently, the thrombotic risk associated with low protein C levels 
was confirmed in the Leiden Thrombophilia Study (LETS). In this case-control 
study, including 474 patients and control subjects, the risk of venous thrombosis 
appeared to be four times higher in persons with protein C levels below 65% com-
pared to individuals with a protein C level equal to or above 85%6.
Age, sex and lifestyle or biochemical factors such as body mass index, LDL-
cholesterol, HDL cholesterol, triglycerides, oral contraceptive use and cigarette 
smoking may influence protein C levels8,9. Protein C levels can also be influenced 
by genetic factors. An analysis within the LETS showed a genetic variant in the 
promoter region of the protein C gene which was associated with low protein C 
levels and an increased risk of deep venous thrombosis of the leg10. Individuals 
with the homozygous CGT genotype of the polymorphisms at -2405, -2418 and 
-2583 (in LETS defined as polymorphisms at -1654, -1641 and -1476) were found to 
have a 1.5- to two-fold greater risk of venous thrombosis than individuals with the 
homozygous TAA genotype. Two out of three polymorphisms investigated in the 
LETS (2405C/T and 2418A/G) were considered as functionally different and were 
evaluated again in a study including 242 patients with deep venous thrombosis and 
394 healthy individuals11. This study confirmed the link between these protein C 
gene polymorphisms and circulating protein C levels. Both studies did not evaluate 
the relationship between protein C levels and the risk of venous thrombosis.
Due to the relatively small number of participants in these previous studies, the 
risk estimates from these studies were imprecise and the joint effect of the protein 
C polymorphisms with other risk factors for venous thrombosis could not be inves-
tigated. The factor V Leiden mutation, which is the most common known cause of 
inherited thrombophilia, causes activated protein C resistance12. Oral contracep-
tive use, another important risk factor for venous thrombosis, also contributes to 
activated protein C resistance13. Since a previous study showed that deficiency of 
protein C and the factor V Leiden mutation had synergistic effects14, as does the 
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combination of factor V Leiden and oral contraceptive use15, it is of interest to 
investigate the risk of venous thrombosis in individuals with factor V Leiden or 
oral contraceptive use and the genotype associated with low protein C levels.
In the Multiple Environmental and Genetic Assessment of risk factors for venous 
thrombosis (MEGA study), a large population-based case-control study, we investi-
gated the two polymorphisms within the protein C gene (2405C/T and 2418A/G) as 
risk factors for venous thrombosis. We also investigated the influence of genotypic 
variation on plasma protein C levels and the effect of protein C levels on the risk of 
venous thrombosis. In addition, the joint effect of the low protein C genotype with 
the factor V Leiden mutation and oral contraceptive use was investigated.
methods
Study Design
The MEGA study included consecutive patients with a first diagnosis of venous 
thrombosis. Patients were selected from the files of the anticoagulation clinics in 
Amsterdam, Amersfoort, The Hague, Leiden, Rotterdam and Utrecht between 
March 1999 and September 2004. In the Netherlands, anticoagulation clinics 
monitor anticoagulation treatment in all patients in a geographically well-defined 
area. Patients between the age of 18 and 70 with a deep venous thrombosis of the 
leg, a pulmonary embolism or a combination of these diagnoses were included in 
our study. For practical reasons, patients with severe psychiatric problems or those 
unable to speak Dutch were considered as ineligible.
Partners of patients were asked to participate as control subjects. From January 
2002 until September 2004, additional control subjects were recruited by using 
the random digit dialing (RDD) method16. The random control subjects were 
frequency matched on age and sex to the patients that provided a blood sample. 
Only control subjects without a history of venous thrombosis were included and 
the same exclusion criteria were applied as for the patients.
All participants were asked to fill in a questionnaire about possible risk factors 
for venous thrombosis. Most questions referred to a period of 12 months prior 
to the index date, i.e. the date of diagnosis of the thrombosis of the patient for 
patients and partners and the date of filling in the questionnaire for the random 
control subjects. Of the variables known to influence protein C levels we collected 
information on age, sex, body mass index (weight/height2, kg/m2), smoking and 
oral contraceptive use.
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Blood collection
At least three months after withdrawal of anticoagulation the patients and their 
partners were asked to visit the anticoagulation clinic after an overnight fast, and 
a blood sample was drawn. Only in case of continuous use of anticoagulants for 
more than one year a blood sample was taken during anticoagulation therapy. 
From December 1999 onwards, we obtained self-administered buccal swabs by 
mail when participants were unable or unwilling to come for a blood draw. From 
June 2002 onwards, blood draws were no longer performed in patients and their 
partners, and the study was restricted to DNA collection by buccal swabs sent 
by mail. The random controls were invited for a blood draw within a few weeks 
after the questionnaire was sent. Within this group buccal swabs were sent when 
someone refused the blood draw.
Of the 6237 eligible patients, 276 died soon after the venous thrombosis. Of the 
remaining 5961 patients 4957 participated (83%). A blood sample was provided 
by 2349 patients, a buccal swab was obtained from an additional 1940 patients. 
Genotyping was successful in 4285 patient samples for the 2405C/T polymorphism 
(rs1799808) and in all 4289 samples for the 2418A/G polymorphism (rs1799809). 
Numbering of the polymorphisms was according to GB:AF378903. Protein C levels 
were successfully measured in 2347 out of 2349 blood samples.
Of the 4957 participating patients, 3581 had an eligible partner. One partner 
died soon after the request for participation. Of the remaining 3580 partners, 2917 
participated (81%). An additional 173 control subjects were included of whom 
the partner was excluded for the final patient analysis, 121 partners were included 
of whom the patient had a deep venous thrombosis of the arm and 20 partners 
of non-participating patients were included, resulting in a total of 3231 partners. 
Within the partner group, 1465 blood samples and 1377 buccal swabs were obtained. 
Genotyping was successful in 2840 partners for the 2405C/T polymorphism and in 
all 2842 samples for the 2418A/G polymorphism. Protein C levels were successfully 
measured in 1463 out of 1465 blood samples.
Of the 4350 eligible RDD control subject, four died before they were able to par-
ticipate. Of the remaining 4346 persons, 3000 participated (69%). A blood sample 
was provided by 1437 RDD control subjects, a buccal swab by 586 RDD controls. 
The 2405C/T and 2418A/G polymorphisms were successfully determined in all 
2023 DNA samples and protein C levels in 1436 out of 1437 blood samples.
The 2405C/T and 2418A/G polymorphisms were determined by 5’nuclease (Taq-
man; Applied Biosystems, Foster City, CA) assays using a standard PCR reaction 
mix (Eurogentec, Seraing, Belgium) and allele-specific fluorescent probes equipped 
with a minor groove binding moiety (Applied Biosystem). A detailed description 
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of blood collection and DNA analysis for the factor V Leiden (G1691A) mutation 
in the MEGA study has been published previously17. For practical reasons, we only 
included 4285 patients and 4863 control subjects in the analyses with complete 
data for both polymorphisms. Measurement of protein C level was done with a 
chromogenic assay on a STA-R coagulation analyzer following the instructions of 
the manufacturer (Diagnostica Stago, Asnières, France). The mean intra- and inter-
assay coefficients of variation were 1.4 % and 3.5 %. In the analyses with protein C 
levels, individuals using oral anticoagulation or with protein C deficiency (protein 
C levels below 66%, according to the clinical cut-off value) were excluded, resulting 
in 2043 patients and 2857 control subjects. In this excluded group, frequencies of 
the genotypes were comparable to those in the general population.
All participants gave written informed consent. The study was approved by the 
Medical Ethics Committee, Leiden University Medical Center, The Netherlands.
Statistical analysis
We pooled the control groups and calculated unmatched odds ratios (ORs). ORs 
and 95% confidence intervals (CI95) were calculated according to the method 
of Woolf18. With a multiple logistic regression model ORs were adjusted for age 
(continuous) and sex (categorical). SPSS for Windows version 14.0.1 (SPSS Inc, 
Chicago, Ill) was used for all statistical analyses.
results
In the present analyses 4285 patients and 4863 control subjects were included. Mean 
age of patients was 48.5 years (5th-95th percentiles, 26.1-67.7) and control subjects 
were on average 47.9 years old (5th-95th percentiles, 26.8-66.7). In the patients 58% 
(n=2491) were diagnosed with a deep venous thrombosis of the leg, 33% (n=1398) 
with a pulmonary embolism and 9% (n=396) with both. Fifty-four percent of 
patients (n=2324) and 53% of control subjects (n=2590) were women. Within the 
patient group with measured protein C levels, 281 out of 2347 patients (12%) were 
using oral anticoagulation compared to 28 out of 2899 (1%) in the control group 
at the time of blood draw. An additional 23 patients and 14 control subjects were 
potentially protein C deficient (protein C levels below 66%). When participants 
who used oral anticoagulation therapy or who were potentially protein C deficient 
were excluded, protein C levels were 118.2% (5th-95th percentiles, 87.0-160.0%) in 
patients and 117.9% (5th-95th percentiles, 88.0-155.0%) in control subjects.
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The genotype distributions of the 2405C/T and 2418A/G polymorphisms in the 
overall group are presented in table 1. The distribution of both polymorphisms 
did not differ from Hardy-Weinberg equilibrium in control subjects. The T allele 
was present in 34% of patients and 35% of control subjects. Compared to the CC 
genotype, the TT genotype had a reduced risk of venous thrombosis (OR 0.85, CI95 
0.74-0.97). This protective effect disappeared after adjustment for the 2418A/G 
polymorphism (OR 1.03, CI95 0.87-1.23). For the 2418A/G polymorphism, the G 
allele was slightly more frequent in patients (47%) than in control subjects (43%). 
The GG genotype had a small increase in risk of venous thrombosis compared 
table 1. Frequency of protein C polymorphisms 2405C/T (rs1799808) and 2418A/G (rs1799809) in 
patients and control subjects and their relative risk of venous thrombosis
Patients
n %
Control subjects
n %
OR (CI95)*
2405C/T
CC 1887 44.0 2037 41.9 1 (ref.)
CT 1913 44.7 2208 54.4 0.93 (0.86-1.02)
TT  485 11.3  618 12.7 0.85 (0.74-0.97)
T allele freq. 33.6  35.4
2418A/G
AA 1230 28.7 1575 32.4 1 (ref.)
AG 2122 49.5 2358 48.5 1.15 (1.05-1.27)
GG  933 21.8  930 19.1 1.29 (1.14-1.45)
G allele freq. 46.5 43.4
OR, odds ratio; CI95, 95% confidence interval; ref., reference category
* adjusted for age and sex
table 2. Protein C (PC) levels in different genotypes/haplotype combinations
Genotype
SNP
2405/2418
Haplotype
Combinations
Patients
n
Mean PC
level
%   SD
Control subjects
n
Mean PC
level
%   SD
CC/AA CA/CA 94 123   22 108 122   24
CT/AA CA/TA 291 123  23 443 123   20
TT/AA TA/TA 233 123   22 362 121   20
CC/AG CA/CG 360 117   21 550 118   20
CT/AG TA/CG* 625 118   22 840 117   22
TT/AG TA/TG 2 129   30 5 112   11
CC/GG CG/CG 437 113   21 549 112   18
CT/GG CG/TG 1 129   -- 0
Total 2043 2857
SD, standard deviation
* Most likely haplotype combination since the TG haplotype of the alternative CA/TG combination is very 
rare
Note: Individuals with oral anticoagulation therapy or protein C deficiency were excluded
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to the AA genotype (OR 1.29, CI95 1.14-1.45). After adjustment for the 2405C/T 
polymorphism the risk remained 1.3-fold increased (OR 1.31, CI95 1.13-1.53).
In table 2 protein C levels for the various combinations of the two polymorphisms 
are presented. Of the nine possible genotypes, six were frequently observed, two 
were rare and one was not observed. Within the six frequent genotypes, the CC/GG 
genotype was associated with low mean protein C level in control subjects (112%), 
the CC/AG and CT/AG genotypes had intermediate protein C levels (respectively, 
118 and 117%) and the CC/AA, CT/AA, TT/AA genotypes were associated with 
high protein C levels (121 to 123%). A similar pattern was found in patients.
Table 3 presents the association of the six frequent genotypes with the risk of ve-
nous thrombosis. We chose one of the homozygous genotypes with a high protein 
C level (TT/AA) as the reference group. Compared to the TT/AA genotype the 
CC/GG genotype was associated with the highest increase in risk (OR 1.27, CI95 
1.09-1.48). Factors that are known to influence protein C levels did not account 
for this increased risk; after additional adjustment for body mass index, smoking 
and oral contraceptive use the risk estimate remained unchanged (OR 1.33, CI95 
1.13-1.56).
To verify whether the effect of the CC/GG genotype on the risk of venous 
thrombosis was in fact mediated via protein C levels, we also investigated whether 
a decrease in protein C levels was associated with an increased risk of venous 
thrombosis. Variations of the PC levels within the normal range were however not 
clearly associated with the risk of venous thrombosis. With protein C as a continu-
ous variable in the logistic model no increased risk was observed (OR 0.99, CI95 
0.99-0.99). With protein C as a categorical variable only protein C levels below 81% 
(compared to protein C levels between 111 and 120%) appeared to be associated 
table 3. Relative risk of venous thrombosis according to genotype
Genotype Patients Control subjects OR (CI95)*
TT/AA 482 612 1 (ref.)†
CT/AA 561 764 0.93 (0.79-1.10)
CC/AA 187 199 1.19 (0.95-1.51)
CT/AG 1342 1438 1.19 (1.03-1.36)
CC/AG 777 914 1.08 (0.93-1.26)
CC/GG 923 924 1.27 (1.09-1.48)
OR, odds ratio; CI95, 95% confidence interval; ref., reference category
*adjusted for age and sex
† The TT/AA genotype was chosen as reference category, because it was associated with high protein 
C levels, was highly prevalent and was reported as reference category in previous studies thereby 
facilitating comparison between study results
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with a moderately, but not significant increased risk of venous thrombosis (OR<75% 
1.52, CI95 0.75-3.07; OR76-80% 1.24, CI95 0.71-2.17).
In table 4 the joint effect of factor V Leiden and the CC/GG protein C genotype is 
presented. The TT/AA genotype combined with factor V Leiden resulted in a 4.0-
fold increased risk (OR 3.96 CI95 2.54-6.18) compared to TT/AA carriers without 
the mutation. Relative to TT/AA carriers without the factor V Leiden mutation, the 
joint effect of factor V Leiden and the GG/CC genotype led to a 4.7-fold increased 
risk (OR 4.65, CI95 3.24-6.68).
The joint effect of the CC/GG genotype together with oral contraceptive use in 
women younger than 50 is also presented in table 4. The TT/AA genotype com-
bined with oral contraceptive use resulted in a 4.3-fold increased risk of venous 
thrombosis, compared to non-users with the TT/AA genotype (OR 4.33, CI95 
2.67-7.01). The CC/GG genotype together with oral contraceptive use was associ-
ated with a 5.2-fold increased risk (OR 5.16, CI95 3.32-8.00) compared to TT/AA 
carriers without oral contraceptive use.
In addition to these analyses, we also investigated the combined effect of the 
CC/GG genotype with body mass index, since obesity is also related to activated 
protein C resistance. We found no synergistic effect for the combination of the CC/
GG genotype and obesity (data not shown).
table 4. Combined effect of two protein C genotypes with factor V Leiden (FVL) or oral contraceptive (OC) 
use1 on the risk of venous thrombosis
Genotype FVL Patients Control subjects OR (CI95)*
TT/AA - 403 583 1 (ref.)
CC/GG - 781 877 1.29 (1.10-1.51)
TT/AA + 79 29 3.96 (2.54-6.18)
CC/GG + 140 44 4.65 (3.24-6.68)
OC use
TT/AA - 43 100 1 (ref.)
CC/GG - 107 163 1.53 (0.99-2.35)
TT/AA + 110 59 4.33 (2.67-7.01)
CC/GG + 202 91 5.16 (3.32-8.00)
1 in women aged 18 to 49
OR, odds ratio; CI95, 95% confidence interval; ref., reference category; -, absent; +, present
* adjusted for age and sex (not adjusted for sex in OC analysis)
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discussion
In a large population-based case-control study, we investigated two polymor-
phisms, 2405C/T and 2418A/G, within the protein C gene as risk factors for venous 
thrombosis. The T allele at position 2405 was associated with a protective effect and 
the G allele at position 2418 was associated with a small increased risk of venous 
thrombosis compared to the C and A alleles at these positions. Combining these 
alleles into different genotypes revealed that the CC/GG genotype was associated 
with low protein C levels compared to the other genotypes. The CC/GG genotype 
was associated with a 1.3-fold increased risk of venous thrombosis compared to 
the TT/AA genotype, which was a genotype with relatively high protein C levels. 
There were only minor synergistic effects of the CC/GG genotype with the factor V 
Leiden mutation or oral contraceptive use.
An increased risk for the C and G alleles compared to the T and A alleles is in ac-
cordance with the findings of previous studies10,11. The finding of low protein C lev-
els in carriers of the homozygous CC/GG genotype is also in agreement with these 
studies10,11. The G allele at 2418 in the genotype seemed to be the most important 
determinant of protein C levels. Carriers of genotypes without a G allele presented 
relatively high protein C levels, carriers of genotypes with one G allele had interme-
diate levels and carriers of the genotype with two G alleles had the lowest protein 
C level. Homozygosity or heterozygosity for the 2405C/T polymorphism was less 
important in the determination of protein C levels, indicating that the effect on 
protein C levels was mainly mediated by the 2418A/G polymorphism. To verify 
this, we calculated the relative risk of the 2405C/T polymorphism adjusted for the 
2418A/G polymorphism. As was expected the effect of the 2405C/T polymorphism 
disappeared. In contrast, the relative risks of the 2418A/G polymorphism remained 
elevated after adjustment for the 2405C/T polymorphism. In this study 19.1% of the 
control subjects, who represent the general population, had the GG genotype. This 
suggests that 5% of all venous thrombotic disease is associated with this genotype 
(population attributable risk: 5.1%).
In accordance with the finding of the lowest protein C levels in the CC/GG geno-
type we found the highest risk of venous thrombosis for carriers of this genotype. To 
verify whether the effect of the CC/GG genotype on the risk of venous thrombosis 
was truly mediated via protein C levels, low protein C levels themselves had to be 
associated with an increased risk of venous thrombosis. We found a moderately 
increase in risk, only for protein C levels below 81%. It seems that the risk of venous 
thrombosis is only influenced by protein C levels in the very low range. This is 
supported by the findings of a case-control study in women aged 45 to 64 years that 
reported a 2.9-fold increased risk for levels below 81 iu/dl19. In addition, we found 
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a 2.9-fold increased risk of venous thrombosis (CI95 1.25-6.73) in individuals with 
protein C levels below 66%. Previous studies on the 2405 C/T and 2418A/G poly-
morphisms10,11 did not evaluate the relationship between protein C levels and the 
risk of venous thrombosis. In our analysis, the exclusion of individuals with oral 
anticoagulation therapy could have resulted in a small underestimation of risk esti-
mates in the lower range. It is very likely that protein C levels of the excluded group 
were not evenly distributed throughout the categories; individuals with relatively 
low protein C levels were probably overrepresented in the excluded group.
We also assessed the combined effect of the CC/GG genotype with the factor V 
Leiden mutation or oral contraceptive use, which both lead to resistance to activated 
protein C12,13. Previously, a family study showed that a higher percentage of family 
members with both protein C deficiency and the factor V Leiden mutation had 
developed thrombosis (73%), compared with family members with either protein 
C deficiency (36%) or the factor V Leiden mutation (10%) (P < 0.001 for both 
groups). Of the subjects lacking both the mutations, only 7% had experienced a 
thrombotic episode14. In our study however, factor V Leiden together with the CC/
GG genotype resulted in a 4.7-fold increased risk, which was only slightly higher 
than the sum of the separate effect of the CC/GG genotype and factor V Leiden. 
Also for the combination with oral contraceptive use or obesity no substantial 
synergistic effects were found.
In conclusion, the MEGA study confirmed the link between the CC/GG geno-
type, low protein C levels and an elevated risk of venous thrombosis. The increase 
in risk for the CC/GG genotype was mainly mediated by the presence of the G 
allele for the A/G 2418 polymorphism. CC/GG carriers, who were also factor V 
Leiden carriers or oral contraceptive users, did not have a substantial higher risk 
than expected based on the effect of each factor separately.
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abstract
In a large case-control study on risk factors for venous thrombosis (MEGA study) 
we enrolled two different control groups; partners of patients and a random digit 
dialing group (RDD). This presented unexpected challenges in the analysis of three 
different types of research questions. For the evaluation of body mass index, a 
general life style factor, partners had to be analyzed with a matched analysis, RDD 
controls with an unmatched analysis. We developed a statistical approach which 
enabled us to pool the results of both analyses. For the analysis of pregnancy as risk 
factor for venous thrombosis only in women, simple pooling of both control groups 
was possible. However, lower pregnancy rates than expected were encountered 
in the partner group and higher rates in the RDD group. After combining both 
control groups, pregnancy frequencies were comparable with data from the general 
Dutch population. Frequencies of the factor V Leiden mutation, an example of a 
genetic risk factor, were identical in both control groups and in line with published 
data, indicating that for the analyses of this genetic risk factor both control groups 
were equally suitable. Our experience with the inclusion of two different control 
groups might be useful to others for choosing the most optimal research design 
and statistical approach.
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introduction
When designing a case-control study a very important decision is the choice of 
the appropriate control group. The purpose of a control group in a case-control 
study is to indicate the expected frequency of an exposure in patients under the 
null-hypothesis that there is no relation between exposure and disease. Therefore 
a uniform requirement for control selection is that the control group should be 
selected from the same source population as the cases independently of their ex-
posure status1;2.
This general aim nevertheless leads to several options in practice. Control 
subjects can be selected from the general population, such as random population 
control subjects, partners, friends or neighbors. Another potential source of con-
trol subjects is the hospital in which cases are hospitalized. Usually, there will be 
advantages for one group that are missing in the other, and vice versa. For example, 
random population controls may be more difficult to locate and less motivated to 
take part in the study than partners, friends or neighbors3. Situations arise in which 
the investigator may face a choice between two or more possible control groups to 
use. When different types of research questions are addressed and adjustment for 
different variables is required, multiple control groups can be useful. However, it 
has been suggested that the value of multiple control groups is limited1, since it can 
lead to inconsistent results and proper analysis may become complex.
In the Multiple Environmental and Genetic Assessment of risk factors for venous 
thrombosis (MEGA study), a very large population-based case-control study, we 
believed to have good reasons to include two different control groups, a partner 
control group and a random population control group. We included partners be-
cause the main focus of the study was on genetic risk factors for venous thrombosis 
and their interaction with environmental and lifestyle factors. It seemed unlikely 
that partners would select each other based on genetic differences in coagulation 
parameters. We also wanted to study environmental factors that are closely linked 
to lifestyle and for which partner controls might control for unmeasured confound-
ing. In addition we assumed that asking partners would make it easier to recruit 
control subjects with malignancies or chronic diseases, which was a requisite if we 
wanted to study these diseases in relation to the risk of venous thrombosis. For 
the analysis with partner controls we had envisaged either a matched analysis of 
partners or an unmatched analysis with the opposite sex partners of cases becom-
ing controls for same-sex cases. However, the proportion of men and women in 
the patient and control group was different in specific age categories; in particular 
there were very few young men with venous thrombosis (cases), resulting in few 
young female partners (controls), while there were many young female cases of 
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venous thrombosis. A population control group was added, that would be use-
ful for certain analyses (such as pregnancy in young women), and might increase 
the overall numbers for the genetic analyses – as we did not expect differences in 
genetic make-up between partner controls and population controls. In the analy-
sis phase, however, we learned that we had to distinguish quite carefully which 
analyses would be done with what control groups, as there were some unexpected 
differences, predominantly in environmental and lifestyle factors. In the process, 
we also had to devise a method for statistically combining the control groups if the 
analysis with one control group had to be matched and the other not. This process, 
as well as our solutions, might be useful to others who embark on large-scale gene 
environment interaction studies.
meGa study
Patients and partners
Between March 1999 and September 2004, we included consecutive patients with 
a first diagnosis of venous thrombosis. Patients were selected from the files of six 
large anticoagulation clinics in the Netherlands, which monitor anticoagulation 
treatment in all patients in a geographically well-defined area. Patients between the 
age of 18 and 70 with deep venous thrombosis of the leg, pulmonary embolism or 
a combination of these diagnoses were included. Patients with severe psychiatric 
problems or those unable to speak Dutch were considered as ineligible for practical 
reasons.
During the inclusion period partners of patients were asked to participate as con-
trol subjects. Only partner control subjects between the age of 18 and 70 with no 
history of deep venous thrombosis were included and the same exclusion criteria 
were applied as for patients.
Random digit dialing control subjects
From January 2002 until September 2004, another control group was recruited 
by using the random digit dialing (RDD) method according to Waksberg4. Only 
RDD control subjects between the age of 18 and 70 with no recent history of deep 
venous thrombosis were included and the same exclusion criteria were applied as 
for patients. The RDD method has proved to be a constructive method to collect a 
nearly random sample of all individuals in the population5. This method employs a 
two stage design which increases the likelihood of contacting households. Within 
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the geographical inclusion area, area codes and prefix numbers (first three digits of 
personal telephone number) combinations were obtained. For efficiency reasons, 
the prefixes were not generated completely at random in our study but were gener-
ated from the prefix numbers of the patients. To these prefixes, different random 
combinations of the next two digits were added. These eight digits formed the first 
stage of the sampling unit, i.e. the Primary Sampling Units (PSUs). To each PSU 
again two digits were added which were randomly generated by the computer. This 
number was dialed to determine whether or not it reached a household. If it did 
not reach a household because the telephone number was not in use or was used 
by a business or institution, the PSU was dropped from further consideration. If it 
did reach a household, 19 new numbers with the same PSU were randomly gener-
ated by the computer. Per household a maximum of seven attempts were made at 
different time points of the day and at different week days, with once at least three 
weeks between two attempts.
This procedure of control sampling was expensive and time-consuming; on 
average only three persons per hour were included. The response rate is hereby 
dependent on demographic characteristics of the target population and telephone 
skill of the interviewers5. In addition the RDD method is only useful if the vast ma-
jority of individuals live in households with a fixed telephone. In December 2005 
fixed telephone coverage in the Netherlands was still very high (96%)6, indicating 
that telephone coverage was more than enough for our RDD method. However 
in the nearby future, increasing use of mobile phones will decrease the ability for 
the RDD method to target specific areas within a country and achieve complete 
coverage.
An important consideration in random digit dialing surveys is bias introduced 
by non-responders. Non-response bias can be a problem if responders differ from 
non-responders for the measured variables7;8. Most studies have found that reluc-
tant respondents are older and less educated than respondents who readily agree. 
Differences with respect to income, occupation, race and marital status have been 
inconsistent8.
For efficiency reasons, we frequency matched the random control subjects to 
the patients who provided a blood sample according to age and sex. With each 
telephone call we asked a specific person within a household to participate (e.g. 
youngest woman between 20 and 50) and therefore avoided that the first person 
who picked up the phone, who maybe more mobile and healthier, was constantly 
included as control subject.
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Data collection
Within a few weeks after diagnosis and registration at the anticoagulation clinics 
patients received a letter with information about the study and were subsequently 
contacted by phone. Partners of patients were also invited to participate. If patients 
or partners refused to participate the reason for refusal was asked for. Patients, 
partners and random digit dialing control subjects received a questionnaire shortly 
after inclusion by phone. The questionnaires included items on potential risk fac-
tors for venous thrombosis e.g. body weight, body height and pregnancies. Most 
questions referred to a period of 12 months prior to the index date, i.e. the date of 
diagnosis of thrombosis of the patient or the date of filling in the questionnaire 
for the random control subjects. For partners the date of diagnosis of thrombosis 
of the patient was used as index date in the body mass index analyses and in the 
pregnancy analyses the date of filling in the questionnaire was used.
From March 1999 till June 2002, patients and their partners were asked to visit 
the anticoagulation clinic where after an overnight fast a blood sample was drawn 
at least three months after withdrawal of anticoagulation. Only in case of continu-
ous use for more than one year a blood sample was taken during anticoagulation 
therapy. From December 1999 onwards, self-administered buccal swabs were 
obtained by mail when participants were unable or unwilling to provide a blood 
sample. From June 2002 onwards, blood draws were no longer performed in pa-
tients and their partners, and the study was restricted to DNA collection by buccal 
swabs sent by mail. The RDD controls were invited for a blood draw within a few 
weeks after the questionnaire was sent. Within this group buccal swabs were sent 
when someone refused the blood draw. In the blood samples and buccal swabs 
prothrombotic mutations including the Factor V Leiden (G1691A) mutation were 
determined. A detailed description of blood collection and DNA analysis for factor 
V Leiden in the MEGA study has been published previously9.
resPonse rates and General characteristics
During the inclusion period, 5961 eligible patients, 3586 eligible partners and 4346 
eligible RDD control subjects were approached to participate. In the patient group, 
4957 patients (83%) were willing to participate, partners had a similar response 
rate (n=2917, 81%), and 3000 (69%) RDD control subjects participated (figure 1).
Of the participating patients 92% returned a questionnaire compared to 95% 
and 93% in partners and RDD control subjects. During the first part of the 
MEGA study (March 1999-June 2002) a blood sample was provided by 73% of 
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participating patients and 70% of partners. Forty-eight percent of eligible RDD 
control subjects provided a blood sample. During the second part of the study 
(June 2002-September 2004), a buccal swab was obtained from 86% of patients 
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Figure 1. Response rates of patients, partners and RDD control subjects
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and 89% of partners. Reasons why persons refused to participate are presented in 
more detail in table 1.
Mean age of 4957 patients was 48.6 (5th-95th percentiles, 25.7-67.9), the 2917 
partners were on average 48.3 years (5th-95th percentiles, 28.0-66.1) and the 3000 
RDD control subjects had a mean age of 45.3 (5th-95th percentiles, 23.5-66.9). Fifty 
four percent (n=2680) of patients, 50% (n=1463) of partners and 57% (n=1719) of 
RDD control subjects were women.
diFFerent research questions, diFFerent use oF controls
In the MEGA study we investigated genetic or acquired factors and their interac-
tion as possible risk factors for venous thrombosis. As genetic risk factors several 
prothrombotic mutations, such as the factor V Leiden mutation, were measured 
in blood samples or buccal swabs collected from the participants. Included were a 
wide range of acquired risk factors like malignancies, surgery, injuries and various 
lifestyle related risk factors as pregnancy, oral contraceptive use, overweight, smok-
ing, physical activity, alcohol use and (air) travel. When analyzing lifestyle factors 
as possible risk factors for venous thrombosis different considerations concerning 
the choice of a control group have to be made compared to the analysis of genetic 
risk factors. It is challenging to use both control groups in such a way that statistical 
power is maintained and bias is reduced to a minimum.
For set forth the analytic considerations of two different control groups we will 
describe the association of a general lifestyle risk factor (body mass index), a 
lifestyle risk factor in women (pregnancy) and an example of a genetic risk factor 
(factor V Leiden mutation) with the risk of venous thrombosis. We will present 
table 1. Reasons for non-response in patients, partners and RDD control subjects
Control subjects
Patients
N %
Partners of participating 
patients
N %
RDD controls
N %
Refused to participate 922 100 651 100 1331
No willingness 514 55.7 628 96.5 1243 93.4
Too many hospitals 93 10.1 – –
Not mobile 17 1.8 1 0.2 –
Untraceable 271 29.3 14 2.2 88 6.6
Filled in questionnaire about 
recurrent VT
5 0.5 – –
Reason unknown 22 2.4 8 1.2 –
– = not specified
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a statistical method that allowed us to use both control groups in the analyses of 
body mass index as risk factor for venous thrombosis.
Body mass index- General lifestyle risk factor
For the analyses of body mass index (BMI) as risk factor for venous thrombosis10 
the most obvious control group seems to be the RDD control group because one 
instinctively would say that partners are too much alike. When we investigated 
the BMI distribution in patients, partners and the RDD controls, frequencies of 
overweight (BMI: 25-29 kg/m2) and obesity (BMI: ≥ 30 kg/m2) were indeed more 
similar in patients and their partners than in patients and the RDD controls, result-
ing in lower risk estimates when using the partner control group compared to the 
RDD control group (table 2). These results were obtained with an unconditional lo-
gistical regression analysis, which is not correct because it uses partners of cases as 
control subjects for other cases. Partners are matched with patients and this match-
ing has to be considered in the statistical analysis since ignoring matching generally 
introduces bias, even if the matched variable is not a confounder1. Performing an 
unmatched analysis with matched data will result in an underestimation of the true 
effect. Matching was accounted for with a conditional logistic regression analysis11, 
i.e. matched analysis, which adjusts for similar lifestyle factors between patients 
and their partners by including only discordant pairs. In table 3 the results of the 
matched analysis with patient-partner pairs is presented. Risk estimates appeared 
to be still somewhat lower compared to the analysis with the RDD control subjects 
(overweightpartners OR 1.45, CI95 1.26-1.67; overweightRDD OR 1.83, CI95 1.63-2.05; 
obesitypartners OR 1.81, CI95 1.49-2.20; obesityRDD OR 2.87, CI95 2.45-3.35). A pos-
sible explanation for this difference is that adjustment for similar lifestyle factors 
in the matched analysis may include some unknown, unmeasured confounders, 
which will lead to risk estimates closer to the real estimates compared to the risk 
estimates obtained from the analysis with the RDD controls. It is important to 
table 2. Body mass index (BMI) distribution in patients, partners and RDD control subjects – Unmatched 
analyses
BMI (kg/m2) Patients
N   %
Partners
N   %
RDD
N   %
ORpartner*
(CI95)
ORRDD*
(CI95)
<25 1369  36.5 1306  44.8 1409  55.7 1 1
25-29 1593  42.4 1172  40.2 848   33.5 1.33 (1.20-1.49) 1.83 (1.63-2.05)
≥30 794   21.1 438   15.0 274   10.8 1.75 (1.52-2.01) 2.87 (2.45-3.35)
Total 3756 2916 2531
*adjusted for age and sex
Odds ratios (ORs) calculated with unconditional logistic regression
Note: BMI analyses were performed in non-pregnant individuals without malignancies
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realize that in the matched analysis only patient-partner pairs can be included, 
resulting in less power than the analysis with the RDD control subjects. Besides 
this, both the patient and the partner of a pair must have valid data for the required 
variable, otherwise the whole pair cannot be included in the analysis. Finally, the 
matched analysis itself only uses pairs who are discordant for the variable of inter-
est, resulting in further reduced power.
Using the RDD control subjects in the analyses of BMI as risk factor for venous 
thrombosis may result in a slightly overestimation of the true risk estimates be-
cause there were somewhat fewer RDD controls with overweight compared to the 
general Dutch population. According to data of the Central Bureau of Statistics in 
the Netherlands the prevalence of overweight and obesity was respectively 36% 
and 11% during the study period12, compared to a 33% and 11% found in the RDD 
group.
Both partner and RDD analyses showed consistent results in terms of clearly 
increased risks. In a combined analysis the most powerful estimate was obtained. 
We used a simple approach in which the estimates of the odds ratios of the two 
analyses were pooled13. In this combined analysis we accounted for the correla-
tion between the estimated odds ratios since most patients were included both in 
the matched and the unmatched analysis. Table 4 presents the odds ratios of the 
combined analysis (ORoverweight 1.71, CI95 1.54-1.89, ORobesity 2.45, CI95 2.14-2.80), 
which were of course in between partner and RDD odds ratios.
When analyzing the risks in men and women separately it was not possible to 
perform a matched analysis with the partner controls, as control individuals were 
nearly always of the opposite sex to the cases.
table 3. BMI as risk factor for venous thrombosis - Matched analyses
BMI (kg/m2) Patients Partners ORmatched* (CI95)
<25 739 925 1
25-29 949 860 1.45 (1.26-1.67)
≥30 415 318 1.81 (1.49-2.20)
Total 2103 2103
*adjusted for age and sex
table 4. BMI as risk factor for venous thrombosis - Combined analyses with patients, partners and RDD 
control subjects
BMI (kg/m2) Patients Partners RDD ORcombined* (CI95)
<25 1369 925 1409 1
25-30 1593 860 848 1.71 (1.54-1.89)
≥30 794 318 274 2.45 (2.14-2.80)
Total 3756 2103 2531
*adjusted for age and sex
table 2-4: Adapted from British Journal of Haemaology 2007; 139: 289-269
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Pregnancy- Lifestyle risk factor in women
In the MEGA questionnaire, participants were asked if they had been pregnant in 
the year before the index date or if they were still pregnant, and what the (expected) 
date of delivery was.
In the analysis of pregnancy as risk factor for venous thrombosis, only women 
were included. In addition, only participants with a partner were included in the 
analysis, since being in a relationship affects the probability of getting pregnant. 
During the invitation by phone, patients were asked if they had a partner, partner 
controls had a partner per definition, and civil status was asked for in the question-
naire, also allowing the inclusion of only RDD controls with a partner. However, we 
encountered a much higher frequency of pregnancies in the RDD control subjects 
with a partner than in the partner control subjects (table 5). The percentage of 
pregnant or postpartum women was 12.3% in the RDD control group and 3.9% 
in the partner control group compared to 8.8% in the general population. These 
table 5. Pregnancy and postpartum in patients, partners and RDD control subjects
Pregnancy status Patients
N   %
Partners
N  %
RDD
N   %
ORpartner* ORRDD* ORtotal*
Neither 163   61.3 394   96.1 371   87.7 1 1 1
Pregnant 35   13.2 14   3.4 44   10.4 9.28
(4.37-19.70)
3.60
(2.01-6.44)
4.67
(2.72-8.00)
Postpartum† 68   25.5 2   0.5 8   1.9 198.07
(38.00-
1032.29)
42.22
(17.38-
102.60)
61.21
(27.06-138.48)
Total 266 410 423
*adjusted for age, †three months after delivery
ORs calculated with unconditional logistic regression
Note: Pregnancy analyses were performed using women who were between 18 and 50 years of age, had 
a partner, did not use oral contraceptives or hormone replacement therapy and had no malignancies or a 
partner* with malignancies (*for patients and partner controls).
table 6. Different stages of pregnancy and postpartum in patients, partners and RDD control subjects
Pregnancy status Patients
N   %
Partners
N   %
RDD
N   %
Neither 161   60.5 378   92.2 347   82.0
1st and 2nd trimester 8   3.0 6   1.5 30   7.1
3rd trimester 27   10.2 8   2.0 14   3.3
Puerperium (1-6 weeks) 65   24.4 1   0.2 5   1.2
7 weeks to 3rd month postpartum 3   1.1 1   0.2 3   0.7
4th month to 1 year postpartum 2   0.8 16   3.9 24   5.7
table 5-6: Adapted from Journal of Thrombosis and Haemostasis 2008;6:632-637
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frequencies in the control groups were unexpected; before the start of our study 
we assumed that including partners would make it easier to recruit pregnant indi-
viduals because pregnant women in general would be less motivated to participate 
in a study. However, the opposite appeared to be true. The high frequency in the 
RDD group may be due to more awareness of health issues in pregnant women 
and therefore more willingness to participate than non-pregnant women. The low 
frequency in the partner control group remains difficult to explain.
It was possible to combine the two separate control groups into one large group. 
The prevalence of pregnant or postpartum control women (8.1%) then became 
similar to that of the general population (8.8%). Not only for the overall analysis 
but also for the stratified analysis of different stages of pregnancy and the postpar-
tum period it was important that the proportion of control subjects in each time 
frame during and after pregnancy was a good reflection of the general population 
(table 6). To verify this, we calculated the expected number of controls in each 
period, using data from the general population14. During pregnancy the number 
of controls in the overall group was similar to what we would expect to find (6.9% 
compared to an expected 6.6%). In the first three months postpartum we observed 
a lower number of controls (1.2% compared to an expected 2.2%), possibly due to 
a reduced motivation to participate in our study after child delivery. In the period 
from four months up to one year postpartum the number of controls was still 
somewhat reduced (4.7% compared to an expected 6.6%). These lower proportions 
might have resulted in a slight overestimation of relative risks in the postpartum 
period.
These analyses illustrate that the inclusion of multiple control groups appeared 
to be very useful. A priori assumptions about control group characteristics were 
not in line with the collected data. If only a partner control group or only the 
RDD control group was collected, pregnancy associated risks were either over- or 
underestimated.
Factor V Leiden- Genetic risk factor
For genetic risk factors it is unlikely that their frequency is different in partners 
compared to RDD control subjects. However, the prevalence of factor V Leiden 
is related to ethnicity15 so you could speculate that if partners chose their partner 
according to ethnicity the factor V Leiden distribution in partners would be dis-
similar compared to RDD control subjects. In the MEGA study most participants 
were of Dutch origin, so differences in the distribution of factor V Leiden due to 
intra-racial partnerships were unlikely. For the RDD controls you could hypoth-
esize that RDD controls with a positive family history of venous thrombosis will 
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be more willing to give blood than RDD controls without a positive family history, 
leading to an overestimation of the prevalence of factor V Leiden in this group. 
However, we found the same percentage of individuals with factor V Leiden in the 
partner and the RDD group (partner controls, 5.3%; RDD controls, 5.4%) (table 7). 
Obviously, both percentages could be an overestimation of the true prevalence, but 
the percentages were equal to a previously recorded prevalence of factor V Leiden 
in Caucasians16.
Since both control groups had the same percentage of factor V Leiden carriers 
and this percentage was supported by literature both control groups were combined 
as if they were one in an unconditional logistic regression analysis (table 7).
discussion
In the MEGA study, a large population-based case-control study, we evaluated the 
use of two different control groups, a partner control group and a RDD control 
group, in the analyses of three different types of research questions. We learned 
that we had to distinguish quite carefully which analyses would be done with what 
control groups, as there were some unexpected differences. For the evaluation of 
body mass index, we had to devise a method for statistically combining the control 
groups in the analysis. Using the partner control group asked for a matched analysis 
and for the RDD group an unmatched analysis was required. For pregnancy, simple 
pooling of both female control groups was possible. However, lower pregnancy 
rates than expected were encountered in the partner group and higher rates in 
the RDD group. After combining both control groups, pregnancy frequencies were 
comparable with data from the general Dutch population. Frequencies of the factor 
V Leiden mutation were identical in both control groups and in line with published 
data, indicating that for the analyses of genetic risk factor both control groups were 
equally suitable.
table 7. Factor V Leiden mutation (FVL) in patients, partners and RDD control subjects
FVL Patients
N   %
Partners
N   %
RDD
N   %
ORpartner* ORRDD* ORtotal*
- 3612  84.3 2403  94.7 1914  94.6 1 1 1
+ 675   15.7 134   5.3 109   5.4 3.38
(2.78-4.09)
3.36
(2.72-4.15)
3.36
(2.88-3.92)
Total 4287 2537 2023
*adjusted for age and sex
ORs calculated with unconditional logistic regression
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There are only a few studies reporting their experience with multiple control 
groups. In 1983, Savraky and Clarke wrote a paper that summarizes their expe-
rience in using hospital and neighborhood control subjects17. When testing the 
hypothesis if oxidative hair dyes were carcinogenic, they found to their surprise 
lower rates of hair dye use among 314 hospitals (40.5%) than among 470 neighbor-
hood control subjects (52.8%). Several other striking differences were observed. 
Compared with hospital controls, neighborhood controls were older, ethnically 
more heterogeneous, less likely to be oral contraceptive users and more likely to 
be smokers. The investigators believed that most of these differences arose from 
different lifestyles in the relatively rural region from which the hospital controls 
were derived and in the urban region that provided the neighborhood group. These 
geographical differences demonstrate the importance of selection of patients and 
control subjects from the same source population18. A study investigating the as-
sociation between machining fluid and laryngeal cancer risk used control subjects 
with oral cancer and a stratified random sample of all deaths in a distinct geographi-
cal area as control subjects19. When cases (n=888) were compared to oral cancer 
controls (n=752) high exposure to machining fluids resulted in a 1.5-fold increased 
of laryngeal cancer. However, when cases were compared with population controls 
(n=3594) no increased risk of exposure was found. A possible explanation, besides 
a chance finding, may be that exposure data quality for the cases and oral cancer 
controls may have differed from that of the population controls. These studies il-
lustrate the problem of multiple results; at least one of the results is biased. Only 
further external information could help to evaluate the likely extent of bias in the 
estimates from different controls.
Not only characteristics may differ substantially between control groups, but also 
response rates may vary. In the MEGA study partner controls were more willing 
to participate than RDD controls (83% versus 69%). Especially for blood draws 
the difference was considerable; 70% percent of participating partners and 48% of 
participating RDD controls provided a blood sample. A possible explanation for 
this difference may be that partners motivated each other to participate and were 
able to join each other to the location of the blood draw. Another consideration 
which may explain differences between RDD and partner response rates is the fact 
that partners of non-participating patients were not included in the non-response; 
if a patient refused to participate, we did not ask the patients partner to participate. 
Thus beforehand a selection of more willing couples, with participating patients, 
was made which could have positively influenced the partner response.
In the analyses of BMI as risk factor for venous thrombosis partner controls 
were included in a conditional logistic regression analysis (matched analysis) since 
ignoring matching introduces bias. Aside from the complication of matching, the 
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fact that partners have a relationship may be associated with certain characteristics 
which make partners somewhat different from the source population1.
It is important to realize that a priori assumptions about control group char-
acteristics may not be confirmed by the data. We had the wrong assumption that 
including partners would make it easier to recruit pregnant women or individuals 
with severe diseases. Besides the low frequency of pregnancies in partners, fre-
quencies of malignancies were also different from what we expected; both control 
groups had about the same percentage of malignancies (data not shown). These 
findings could indicate that health issues for RDD controls are an extra motivation 
to participate. The low frequency of pregnancies in partners is however difficult 
to understand. It may be due to the fact that partners were approached via the 
patient. It is possible that because of the pregnancy or disease of the partner, the 
patients decided on their own that their partner was not willing to participate. This 
illustrates the importance of asking in detail reasons for non-response.
In conclusion, when different types of research questions are addressed in a case-
control study, it is important to think thoroughly about control group choice and 
the way controls are to be used in the statistical analyses. We hope the discussion 
of our experience in using multiple control groups can help others to create the 
most optimal study design and statistical approach for answering their research 
questions.
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In the Multiple Environmental and Genetic Assessment of risk factors for venous 
thrombosis (MEGA study), a large population-based case-control study, we inves-
tigated lifestyle factors as risk factors for venous thrombosis. Overweight, smoking 
and alcohol consumption were addressed and pregnancy and the postpartum period 
were evaluated in women. Due to the large sample size of the study it was possible 
to investigate the joint effect of these risk factors with important genetic risk factors 
for venous thrombosis such as the factor V Leiden and the prothrombin 20210A 
mutation. In addition to these lifestyle related risk factors, two polymorphisms 
within the promoter region of the protein C gene were studied as risk factors for 
venous thrombosis and the influence of genotypic variation on plasma protein C 
levels was assessed. Finally, we described our experience with the inclusion of two 
different control groups in the MEGA study.
This discussion evaluates the main findings of this thesis and includes brief sum-
maries of all chapters.
Recent studies indicate that obesity increases the risk of venous thrombosis1-8. In 
accordance with these studies we found that relative to those with a normal body 
mass index (BMI<25 kg/m2), overweight (BMI≥25 and BMI<30 kg/m2) increased 
the risk of venous thrombosis 1.7-fold and obesity (BMI≥30 kg/m2) 2.4-fold. Body 
weight as a separate risk factor for venous thrombosis was also positively associ-
ated with thrombotic risk. Tall men had an increased risk of venous thrombosis, in 
short men a protective effect was found. This latter is remarkable, since body height 
is not associated with the relative amount of fat, in contrast body weight and body 
mass index both are. Biological support for the observed relationship between obe-
sity and the risk of venous thrombosis arises from studies showing an increase of 
procoagulant factors, such as factor VII, factor VIII, factor XII and fibrinogen, with 
increasing body mass index9-12. Together with the fact that the association between 
body mass index and venous thrombosis is consistent over studies and shows a dose 
response relationship, the association is likely to be causal. The effect of obesity was 
more pronounced in women than men, with a 24-fold increased risk for women 
using oral contraceptives compared to normal weight women who did not use oral 
contraceptives. The joint effect of obesity with the factor V Leiden mutation or the 
prothrombin mutation appeared both slightly higher than the sum of the separate 
effects. The synergistic effect of both oral contraceptive use and factor V Leiden 
with obesity may be explained by the fact they all lead to APC-resistance13;14 which 
is associated with a higher risk of venous thrombosis (chapter 2).
The results of studies investigating the relationship of smoking with venous 
thrombosis are inconsistent2;4;6;15;16. In our study, smoking was associated with a 
moderately increased risk of venous thrombosis; in current smokers the risk was 
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1.4-fold increased and former smokers had a 1.2-fold increased risk compared to 
individuals who had never smoked. In current smokers the risk increased with 
the amount of smoking. No dose response relation was found for the number of 
smoking-years in either current or former smokers. In the youngest age category 
(<37.8 yrs) the risk of thrombosis increased with pack-years smoked, with a 4.3-
fold increased risk for smokers with 20 or more pack-years. In those aged over 38, 
no association between pack-years and the risk of venous thrombosis was found. 
The presence of a dose response relationship for the amount but not the duration 
of smoking, the higher risk in current compared to former smokers and the finding 
of a dose response relationship with pack-years in young individuals only, suggests 
that the effect of smoking on venous thrombosis is largely an acute effect. The effect 
of smoking was more pronounced in women than men, which may be explained 
by our finding of a synergistic effect of smoking with oral contraceptive use; 
smoking together with oral contraceptive use resulted in an 8.8-fold increased risk 
compared to non-smokers who did not use oral contraceptives. This interaction 
between smoking and oral contraceptive use is in accordance with the results of 
studies on myocardial infarction17. To investigate a mechanism for the association 
between smoking and venous thrombosis we adjusted our analyses for fibrinogen 
levels, hypothesizing that the risk was mediated via elevated fibrinogen levels. This 
adjustment, however, resulted only in slightly decreased risk estimates for current 
smoking, and therefore fibrinogen levels are not a crucial part of the mechanism. 
Besides coagulation factors, inflammatory factors may be involved. Interleukin-6 
has been shown to be elevated in smokers18 and is also associated with the risk of 
recurrent venous thrombosis19. The involvement of inflammatory factors in the 
etiology of venous thrombosis would be an interesting topic for future research 
(chapter 3).
Moderate alcohol consumption is an established protective factor for cardio-
vascular disease20, however the effect on venous thrombosis is unknown. In the 
MEGA study, alcohol consumption was associated with a decreased risk of venous 
thrombosis, with two to four glasses per day resulting in the strongest effect com-
pared to abstainers. The effect appeared to be more pronounced in women than 
men and for pulmonary embolism than for deep venous thrombosis of the leg. In 
the literature, an association between moderate alcohol intake and reduced levels 
of fibrinogen, factor VII and von Willebrand factor has been reported21 which may 
explain the relationship between alcohol consumption and the reduced risk of ve-
nous thrombosis. In our study, fibrinogen levels were decreased in individuals who 
consumed alcohol compared to abstainers. Factor VII and von Willebrand levels 
were mildly decreased in these individuals but not consistently over the categories 
of alcohol consumption. Therefore, the effect of alcohol seems to be mainly medi-
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ated by a decrease in fibrinogen. The difference between men and women in the 
alcohol-related risk of venous thrombosis may be explained by the differential ef-
fects of wine and beer22, the latter of which is consumed more by men than women. 
The inverse relationship between alcohol consumption and fibrinogen was most 
marked with wine drinking. In our study we had no information about the kind 
of alcoholic drinks the participants consumed. It was striking that the protective 
effect of alcohol was still present at high alcohol intake for pulmonary embolism 
but not for deep venous thrombosis of the leg. We do not have an explanation for 
this finding (chapter 4).
In addition to these common lifestyle factors we also studied a women-specific 
risk factor. In women of reproductive age, over half of all venous thrombotic 
events are related to pregnancy23. During pregnancy, we found a 4.6-fold increased 
risk of venous thrombosis, which is in accordance with the results of other stud-
ies24;25. While previous reports were conflicting about the risk per trimester of 
pregnancy24;26-29, we found the highest risk during the third trimester, namely an 
8.8-fold increased risk. The risk of venous thrombosis during the first six weeks 
after delivery was very high compared to the overall pregnancy-associated risk. 
Our finding of an 84.0-fold higher risk during this period is however within the 
range of findings from the majority of other studies29-31. During pregnancy venous 
thrombosis occurred far more often in the left than in the right leg. In factor V 
Leiden carriers the risk of pregnancy-associated venous thrombosis was 52.2-fold 
increased and 30.7-fold increased in carriers of the prothrombin 20210A mutation 
compared to non-pregnant women without the mutation.
A consideration with the pregnancy analysis is the inclusion of patients through 
anticoagulation clinics. Some women with venous thrombosis during pregnancy 
are initially treated without involvement of the anticoagulation clinic and receive 
low molecular weight heparin (LMWH). Women who had their venous thrombo-
sis during the first or second trimester are more likely to be treated with LMWH 
only than women with a venous thrombosis during the third trimester, the latter 
who are referred to the anticoagulation clinic for additional treatment after child 
delivery. This might have led to an underestimate of the risk of thrombosis during 
early stages of pregnancy in our study (chapter 5).
Besides acquired risk factors, genetic factors play an important role in the etiol-
ogy of venous thrombosis. The factor V Leiden and the prothrombin 20210A muta-
tion are important risk factors, but there are many polymorphisms with a relatively 
small contribution to the risk of venous thrombosis. Two polymorphisms within 
the protein C gene (2405C/T and 2418A/G) were investigated as risk factors for 
venous thrombosis. Out of the various combinations of these two polymorphisms, 
the CC/GG genotype was associated with lowest mean protein C levels and high-
Chapter 8
112
est risk of venous thrombosis. Compared to carriers of the TT/AA genotype - a 
genotype associated with high protein C levels - the relative risk of venous throm-
bosis was 1.3-fold increased in CC/GG carriers. The effect of the CC/GG genotype 
was mainly mediated by the 2418A/G polymorphism; the effect of the 2405C/T 
polymorphisms disappeared after adjustment for the 2418A/G polymorphism. The 
finding of low protein C levels and an elevated risk of venous thrombosis in car-
riers of the homozygous CC/GG genotype is in agreement with other studies32;33. 
To verify if the effect of the CC/GG genotype on the risk of venous thrombosis 
was truly mediated via protein C levels, low protein C levels themselves had to be 
associated with an increased risk of venous thrombosis. Previous studies did not 
investigate this relationship. We found a small increase in thrombotic risk, only 
for protein C levels below 81%. It seems that the risk of venous thrombosis is only 
influenced by protein C levels in the very low range (chapter 6).
In the MEGA study we included two different control groups; partners of patients 
were asked to participate as control subjects and a control group was recruited 
using a random digit dialing (RDD) method. Asking partners as control subjects 
was very practical. They could be approached together with the patient, which was 
very efficient. Another advantage was their high participation rate (81%). They 
were aware of the importance of the study since they had seen the consequences 
of the disease in the patient. Since not all patients had a partner an additional 
control group was recruited with the RDD method. This method has proved to be 
a constructive method to collect a nearly random sample of all individuals in the 
population, but it is expensive and time-consuming. In the MEGA study, sixty-nine 
percent of eligible RDD controls participated.
In chapter 7 we evaluated the analytic possibilities of these two different control 
groups and described the association of a general lifestyle risk factor (body mass 
index), a lifestyle risk factor in women (pregnancy) and an example of a genetic 
risk factor (factor V Leiden mutation) with the risk of venous thrombosis.
When evaluating body mass index as risk factor for venous thrombosis, partners 
and patients have more similar body mass indices than patients compared to random 
digit dialing controls (chapter 2). This matching between patients and partners has 
to be considered in the statistical analysis since ignoring matching generally intro-
duces bias. A conditional logistic regression analysis (i.e. matched analysis) takes 
these similarities into account. It is important to realize that in a matched analysis 
only patient-partner pairs can be included, resulting in less power than an ordinary 
unconditional logistic regression analysis. Besides this, both patient and partner of 
a pair must have valid data for the required variables, otherwise the complete pair 
cannot be included in the analysis. Finally, the matched analysis itself only uses 
pairs who are discordant for the variable of interest, resulting in further reduced 
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power. For the analysis of body mass index, both matched analyses with partners 
and unmatched analyses with RDD controls showed consistent results in terms 
of clearly increased risks. We performed a combined analysis to obtain the most 
powerful estimate. A simple approach was used in which the estimates of the odds 
ratios of the matched and unmatched analyses were pooled34. In this combined 
analysis we accounted for the correlation between the estimated odds ratios since 
most patients were included both in the matched and unmatched analysis.
We assumed that asking partners would make it easier to recruit control subjects 
with pregnancies, malignancies or chronic diseases, which was a prerequisite if 
we wanted to study these diseases in relation to the risk of venous thrombosis. 
However, our pregnancy analysis showed that the opposite was true (chapter 5); 
partner controls group had fewer pregnancies than the RDD group. These findings 
could indicate that being pregnant for RDD controls was an extra motivation to 
participate, which is plausible considering the common knowledge that pregnancy 
is a risk factor for venous thrombosis. Because only women were included in the 
pregnancy analysis, simple pooling of both control groups was possible. In the 
combined control group pregnancy frequencies were comparable with data from 
the general Dutch population. These analyses illustrate that the inclusion of mul-
tiple control groups appeared to be very useful. A priori assumptions about control 
group characteristics were not in line with the collected data. If only a partner 
control group or only the RDD control group was collected, pregnancy associated 
risks were either over- or underestimated.
In the analysis of a genetic risk factor, frequencies of the factor V Leiden muta-
tion were identical in both control groups and in line with published data. For 
the analyses of factor V Leiden as risk factor for venous thrombosis both control 
groups were thus equally suitable and could be simply combined.
Concluding remark
In the past, lifestyle factors as obesity, smoking and alcohol use were only considered 
to be associated with the risk of arterial disease. In this thesis we show that these 
factors are also related to the risk of venous thrombosis. Nowadays an increasing 
number of ‘arterial risk factors’ are linked with venous thrombosis35;36. This sharing 
of common risk factors between arterial and venous thrombosis suggests that the 
link between these two diseases is stronger than previously thought.
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‘The Multiple Environmental and Genetic Assessment of risk factors for venous 
thrombosis’ (MEGA studie) is een groot patiënt-controle onderzoek naar risico-
factoren voor veneuze trombose. In deze studie zijn tussen 1999 en 2004 uit zes 
grote trombosediensten opeenvolgende patiënten in de leeftijd van 18 tot 70 jaar 
geïncludeerd met een eerste veneuze trombose. Als controle personen zijn partners 
van patiënten gevraagd mee te doen en ook werden controles verzameld door mid-
del van een ‘random digit dialing’ (RDD) methode.
In dit proefschrift zijn binnen de MEGA studie verscheidene ‘lifestyle’ factoren 
als risicofactoren voor veneuze trombose onderzocht. Overgewicht, roken en 
alcoholgebruik komen aan bod en ook het gezamenlijk effect van deze factoren 
met genetische risicofactoren voor veneuze trombose, zoals de factor V Leiden 
mutatie en de protrombine 20210A mutatie worden besproken. Daarnaast worden 
zwangerschap en de periode na de bevalling geëvalueerd als risicofactoren voor 
veneuze trombose. Tevens hebben we twee genetische variaties in het promoter 
deel van het proteïne C gen onderzocht als risicofactor voor veneuze trombose 
en de invloed bekeken van deze genetische variatie op de bloedspiegels van dit 
antistollingseiwit. Tot slot hebben we onze ervaringen met de inclusie van twee 
verschillende controlegroepen in de MEGA studie besproken.
Recente studies laten zien dat overgewicht leidt tot een verhoogd risico op veneuze 
trombose. In overeenstemming met deze studies vonden wij in de MEGA studie 
een bijna twee keer verhoogd risico voor individuen met overgewicht (BMI≥25 
en BMI<30 kg/m2) en een 2.5 keer verhoogd risico voor individuen met obesitas 
(BMI≥30 kg/m2) ten opzichte van individuen met een normale ‘body mass index’ 
(BMI<25 kg/m2). Biologische ondersteuning voor deze relatie volgt uit studies 
waarin een verhoging van stollingsfactoren is gevonden met een toename in body 
mass index. Wij vonden een groter effect in vrouwen dan mannen, met een 24-vou-
dig risico in obese vrouwen die de pil gebruikten ten opzichte van vrouwen met een 
normaal gewicht die de pil niet slikten. Het gezamenlijk effect van obesitas met de 
factor V Leiden mutatie en de prothrombine 20210A mutatie was iets groter dan op 
basis van de afzonderlijke effecten verwacht zou worden (hoofdstuk 2).
De resultaten van studies die ingaan op de relatie tussen roken en veneuze trom-
bose verschillen van elkaar. Er wordt zowel melding gemaakt van een verhoging als 
een verlaging van het trombose risico ten gevolge van roken. In the MEGA studie 
bleek roken geassocieerd te zijn met een 1.4-maal verhoogd risico. Wanneer in het 
verleden was gerookt, leidde dit tot een 1.2-maal verhoogd risico ten opzichte van 
individuen die nooit hadden gerookt. In rokers resulteerde een verhoging van het 
aantal sigaretten per dag in een verhoging van het tromboserisico. Er werd geen 
dosis-respons relatie gevonden tussen het aantal rookjaren en het risico op veneuze 
120
Samenvatting
trombose. Een verhoging in pakjaren leidde alleen in de jongste leeftijdscategorie 
(<38 jaar) tot een verhoging van het risico. Het effect van roken was sterker in 
vrouwen dan mannen, wat mogelijk verklaard kan worden door het hoge risico in 
pilgebruiksters. Roken samen met de pil leidde tot een 8.8 keer verhoogd risico. 
Tot op heden is niet duidelijk wat het mechanisme achter de relatie tussen roken en 
veneuze trombose is. Correctie voor het stollingseiwit fibrinogeen leidde niet tot 
een duidelijke risicoverlaging, wat aangeeft dat er andere factoren betrokken zijn 
bij het mechanisme. Daar de ontstekingfactor interleukine-6 verhoogd is in rokers 
en interleukine-6 het risico op een recidief trombose verhoogt, is de betrokken-
heid van ontstekingsfactoren in de etiologie van veneuze trombose interessant voor 
toekomstig onderzoek (hoofdstuk 3).
Matig alcoholgebruik is een bekende beschermende factor voor arteriële cardio-
vasculaire ziekten. Er is echter weinig onderzoek gedaan naar het effect van alcohol 
op veneuze trombose. Alcoholgebruik is in de MEGA studie geassocieerd met een 
verlaagd tromboserisico waarbij het effect het grootst is voor 2 tot 4 glazen per dag. 
In de literatuur wordt matig alcoholgebruik geassocieerd met verlaagde niveaus 
van bepaalde stollingsfactoren, wat het beschermende effect van alcohol mogelijk 
kan verklaren. In onze studie waren met name de niveaus van het stollingseiwit 
fibrinogeen verlaagd in alcoholgebruikers ten op zichte van geheelonthouders 
(hoofdstuk 4).
Vanuit de literatuur is bekend dat voor vrouwen in de vruchtbare leeftijd meer 
dan de helft van alle veneuze tromboses gerelateerd is aan zwangerschap. In de 
MEGA studie laten wij gedurende de zwangerschap een bijna vijf keer verhoogd 
risico op veneuze trombose zien, wat in overeenstemming is met andere studies. 
Tijdens de zwangerschap vonden we het hoogste risico in het derde trimester 
(bijna negen keer verhoogd risico). Postpartum was het risico veruit het hoogst in 
de eerste zes weken na de bevalling; namelijk een 84-voudig risico ten opzichte van 
individuen die niet zwanger of postpartum waren. Zwangerschap in combinatie 
met de factor V Leiden mutatie resulteerde in een ruim 50 keer verhoogd risico ten 
opzichte van niet zwangeren zonder de mutatie. Zwangerschap in combinatie met 
de prothrombine 20210A mutatie resulteerde in een ruim 30 keer verhoogd risico 
(hoofdstuk 5).
Naast lifestyle factoren spelen genetische factoren een belangrijke rol in de 
etiologie van veneuze trombose. De factor V Leiden en de prothrombine 20210A 
mutatie zijn risicofactoren met respectievelijk een minimaal driemaal en tweemaal 
verhoogd risico op veneuze trombose. Er zijn ook vele polymorfismen met een 
kleinere bijdrage aan het tromboserisico. We hebben twee polymorfismen in het 
promoter deel van het protein C gen (2405C/T en 2418A/G) onderzocht. Het CC/
GG genotype was geassocieerd met het hoogste risico op veneuze trombose en met 
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de laagste proteïne C levels. Ten opzichte van het TT/AA genotype – een genotype 
geassocieerd met hoge protein C levels – was het risico op veneuze trombose 1.3 
keer verhoogd in dragers van het CC/GG genotype. Dit resultaat is in overeenstem-
ming met andere studies. Dit effect van het CC/GG genotype bleek voornamelijk 
gemedieerd te worden door het 2418A/G polymorfisme. Om na te gaan of het effect 
van het CC/GG genotype op het tromboserisico werkelijk werd veroorzaakt door 
verandering in protein C levels, moesten lage protein C levels geassocieerd zijn 
met een verhoging van het tromboserisico. Protein C levels onder de 81% waren 
inderdaad geassocieerd met een kleine risicoverhoging (hoofdstuk 6).
In het laatste hoofdstuk hebben we het gebruik van de twee verschillende con-
trolegroepen (partners en RDD controles) geëvalueerd bij het beantwoorden van 
verschillende soorten onderzoeksvragen. Wanneer body mass index onderzocht 
werd als lifestyle risicofactor voor veneuze trombose leken de body mass indices 
van patiënten en partners meer op elkaar dan de body mass indices van patiën-
ten en RDD controles. Voor deze gelijkenis tussen patiënten en partners moest 
gecorrigeerd worden met een zogenaamde gematchte analyse. De RDD controles 
konden geanalyseerd worden met een ongematchte analyse. We ontwikkelden een 
methode om de resultaten van de gematchte en ongematchte analyse te kunnen 
samenvoegen zodat de meest precieze odds ratio werd verkregen.
Bij de analyse van zwangerschap als vrouw-specifieke risicofactor voor veneuze 
trombose konden beide controlegroepen simpel samengevoegd worden. We gingen 
ervan uit dat het includeren van partners het makkelijker zou maken om zwan-
gere controles te includeren. Het tegenovergestelde bleek echter waar te zijn. In de 
partner controlegroep was het percentage zwangeren lager dan in de RDD groep. 
Waarschijnlijk was voor random controles het zwanger-zijn een extra motivatie om 
mee te doen, daar het bij veel vrouwen bekend is dat zwangerschap een risicofactor 
is voor veneuze trombose. Bij samenvoeging van de twee controlegroepen was 
het percentage zwangerschappen gelijk aan dat van de algemene bevolking. Het 
includeren van meer dan één controlegroep was voor deze analyse dus erg nuttig; 
als alleen een partner of RDD groep was geincludeerd waren de risico’s over- of 
onderschat.
Bij de analyse van de factor V Leiden mutatie als genetische factor voor veneuze 
trombose waren de frequencies van deze mutatie in beide controlegroepen gelijk. 
Deze frequentie kwam tevens overeen met de frequentie gerapporteerd in de litera-
tuur. Het is ook niet plausibel dat deelname van controle individuen af zou hangen 
van dit genetische kenmerk. Ook in dit geval konden beide controlegroepen dus 
simpel worden samengevoegd en geanalyseerd met een ongematchte analyse 
(hoofdstuk 7).
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Tot slot
Tot op heden werden lifestyle factoren als obesitas, roken en alcoholgebruik alleen 
geassocieerd met het risico op arteriële ziekten. Tegenwoordig worden echter steeds 
meer ‘arteriële risicofactoren’ geassocieerd met het risico op veneuze trombose. 
Het bestaan van gezamenlijke risicofactoren voor arteriële en veneuze trombose 
suggereert dat de overeenkomst tussen deze twee ziekten groter is dan vooralsnog 
werd aangenomen.
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